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Abstract:  Elizabethkingia are emerging Gram negative opportunistic pathogens and the 
etiologic agents of community- and hospital-associated outbreaks in 
immunocompromised patients.  These organisms are notable for the multiply-antibiotic 
resistant phenotypes all known members express.  While vancomycin is normally 
ineffective against infections caused by Gram negative organisms, this antibiotic has been 
reported to effectively treat Elizabethkingia infections.  Despite increasing interest in 
these organisms, the epidemiology, along with mechanisms by which antimicrobial 
agents, particularly vancomycin, may act on these organisms, and how these organisms 
might acquire resistance to vancomycin, remains poorly understood. 
 
I initially investigated the genomic and antimicrobial profiles of two Elizabethkingia 
anophelis isolates associated with horses. Next, to better understand the interaction of 
antimicrobial agents, particularly vancomycin, with Elizabethkingia, I challenged a 
collection of 21 isolates, including 2 isolates from horses in Oklahoma, representing the 6 
currently described species with vancomycin alone and in combination with other 
antibiotics.  I then assessed how vancomycin challenge impacts the type strain of 
Elizabethkingia anophelis, R26, using RNAseq. Finally, I investigated the mutations 
underlying vancomycin resistance and the physiological consequences of these mutations 
by selecting 8 vancomycin-resistant mutants from 2 different Elizabethkingia species. 
 
Whole genome sequence analysis revealed that the two horse-associated isolates are 
clonal and closely related to human clinical E. anophelis isolates.  These isolates 
displayed antimicrobial susceptibility profiles that were similar to E. anophelis isolates 
from human infections in the United States, including susceptibility to fluoroquinolones 
and resistance to all tested cell wall active antimicrobials.  The other projects revealed 
that vancomycin acts as a bactericidal agent, and likely kills Elizabethkingia through an 
inhibition of peptidoglycan biosynthesis, and induces a stress response that shares many 
characteristics of the oxidative stress response.  Mutations associated with resistance to 
vancomycin rapidly arose after a single vancomycin challenge, and these mutants 
demonstrated altered susceptibility to other antimicrobials and antimicrobial 
combinations.  These mutations uncovered in the vancomycin-resistant mutants occurred 
in an array of genes, suggesting that vancomycin resistance can arise via multiple 
pathways.  This dissertation represents a collection of research that produced data to 
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INTRODUCTION AND REVIEW OF THE LITERATURE 
 
1.1 The Elizabethkingia 
1.1.1 Overview 
Elizabethkingia are Gram-negative opportunistic pathogens and the etiologic 
agents of hospital- and community-acquired infections worldwide [1-4].  These 
organisms are widely distributed and have been found in diverse environments including 
the surface of corn leaves [5], condensation on the Mir space station, soils [6], the 
digestive systems of multiple organisms [7-12], contact lens solutions, and water supply 
systems such as faucets and reservoirs [13].  Elizabethkingia have been associated with 
infections in dogs [14], frogs [15, 16], fish [17], and humans [1, 2, 18-26]. 
 
Originally described by Elizabeth King in 1959, Elizabethkingia were initially 
placed within the genus Flavobacterium as Flavobacterium meningosepticum [27].  New 
isolates were initially grouped by serum agglutination assay, although this technique was 
subsequently displaced by DNA – DNA hybridization studies which added 4 new species 
in addition to F. meningosepticum [28].  New isolates were frequently described as new 




taxonomy of the Elizabethkingia and led to the final revision, where the Elizabethkingia 
genus was formed with Elizabethkingia anophelis and Elizabethkingia endophytica, 
along with E. meningoseptica and E. miricola.  Doijad et al. [30], and Nicholson et al. 
[29] utilized whole genome sequencing and the average nucleotide identity measurement 
to further refine the taxonomy of the Elizabethkingia, with the former determining that E. 
endopyhtica was a subspecies of E. anophelis while the latter characterized the original 
genomospecies which were transferred to the six species that currently comprise the 
genus (Figure 1).  A proposed seventh species consisting of a single isolate identified by 
whole genome sequencing [31]. 
 
From a clinical prespective, the speciation of Elizabethkingia is complicated as 
these organisms do not show consistent phenotypic differences that can be used to 
differentiate these species, and similar problems are encountered when using common 
molecular identification techniques such as 16S rRNA sequencing or MALDI-TOF mass 
spectrometry [29, 32, 33].  All Elizabethkingia isolates sequenced to date contain five 
16S rRNA genes which can demonstrate considerable differences from each other in the 
same organism, and can even harbor 16S sequences that are more related to completely 
different species [29].  The manufacturer’s libraries that are provided with most MALDI-
TOF machines are presently only able to distinguish E. meningoseptica at the species 
level [29, 32].  The Centers for Disease Control and Prevention (CDC) has released 
updated MALDI-TOF libraries that are able to differentiate E. anophelis from E. 





Figure 1. Whole genome single nucleotide polymorphism phylogenetic tree showing the 
six Elizabethkingia species from Nicholson et al. [29].  Reprinted by permission from 




challenge [29].  RpoB sequencing is more reliable, and was able to accurately identify all 
six species, although some difficulties were reported within E. bruuniana, and the CDC 
has released an updated rpoB alignment package to aid in better identification of 
Elizabethkingia isolates by Sanger sequencing [29]. 
 
1.1.2 Epidemiology of Elizabethkingia 
All six currently described species of Elizabethkingia are known to cause 
infections in humans [2, 18, 19, 21, 22, 26, 34-37].  These organisms typically infect 
immunocompromised individuals, particularly neonates [2].  Infections primarily 
manifest as meningitis, although sepsis, endophthalmitis, necrotizing fasciitis, and 
pneumonia have been reported [18, 21-24, 26, 36, 38-63].  Infections caused by 
Elizabehtkingia result in high mortality rates, with reports ranging from 25% to as high as 
75% [1, 35].  Elizabethkingia infections can manifest as isolated cases that typically 
occur in hospitals and can also occur as larger scale outbreaks in both the community and 
hospital settings [4, 35].  The largest outbreak of Elizabethkingia to date was reported in 
Wisconsin during 2015 to 2016 and would eventually grow to a total of 65 cases 
including one case each in Illinois and Minnesota and resulted in 20 deaths [4].  Both 
incidence and prevalence of Elizabethkingia infections are poorly understood, although 
there are reports that suggest the incidence of infection is increasing [21, 44, 64-66].  Hsu 
et al. [44] have conducted the most complete epidemiological survey to date, and report 
that the incidence of infection in Taiwan has increased significantly from 7.5 cases per 
100,000 admissions in 1996 to 35.6 cases per 100,000 admissions in 2006, a five-fold 




with the incidence increasing from 2 per 100,000 admissions in 2009 to 88 per 100,000 
admissions in the first half of 2017. 
 
1.1.3 Antimicrobial resistance in Elizabethkingia 
The most widely used classification scheme has β-lactamases divided into 4 major 
classes, with Class A, Class C, and Class D containing active site serine β-lactamases, 
while Class B contains the metallo-β-lactamases which have at least 1 Zn2+ atom in their 
active sites [67].  These groups are differentiated by conserved amino acid sequences in 
the case of Classes A, C, and D, or by sensitivity to Zn2+ chelation in the case of Class B 
[68].  These enzymes can be further differentiated into enzymes that are narrow spectrum 
or extended spectrum, which reflects the ability of the enzyme to hydrolyze multiple 
classes of β-lactam ring containing antibiotics, and all 4 Classes have both narrow and 
extended spectrum β-lactamase enzymes [67-69]. 
Elizabethkingia are known to be resistant to the majority of β-lactam antibiotics 
as well as most cephalosporins and carbapenems, and are notable in that they express 
three different β-lactamases: Class A serine β-lactamase C. meningosepticum Extended 
Spectrum β-Lactamase (CME) [70], along with two metallo-β-lactamases, the Class B1 
BlaB [71], and the Class B3 GOB [72].  All of these β-lactamases demonstrate broad 
specificities for different β-lactam antibiotics, and differences in the expression of these 
enzymes within Elizabethkingia have been reported [71-73].  In addition to the three 
characterized β-lactamases, bioinformatics suggests that these organisms may also 
contain Class D and Class C serine β-lactamases [4, 5, 7, 9, 10, 12, 37, 61, 74-81], 




proteins it is unclear if these are functional β-lactamases or are penicillin binding proteins 
or other serine hydrolases [82].   
 
While all characterized Elizabethkingia isolates demonstrate resistance to 
aminoglycoside antibiotics, resistance to other antibiotics is variable, with a higher 
prevalence of resistance to fluoroquinolones reported from countries in Asia than 
elsewhere [4, 18, 21, 25, 26, 36, 44, 46-48, 52, 62, 76, 83-85], although the lack of large 
scale studies in other areas severely limits our understanding of antimicrobial 
susceptibility in this genus.  Variable levels of susceptibility are also reported for 
trimethoprim + sulfamethoxazole (6% susceptible to 92% susceptible), piperacillin and 
piperacillin in combination with tazobactam (15% - 100% and 5% - 100%, respectively), 
and tigecycline (5% - 55%) [4, 18, 19, 21, 25, 26, 36, 44, 46-48, 52, 62, 76, 83-89]. 
Elizabethkingia are frequently reported to be susceptible to amikacin, minocycline, and 
rifampin, although isolates resistant to these antibiotics have also been reported [4, 18, 
19, 21, 25, 26, 36, 44, 46-48, 52, 62, 76, 83-89]. Efflux can play a key role in antibiotic 
resistance and function by transporting antibiotics from the cell cytoplasm or periplasm to 
the outside of the cell [90-92].  Efflux pumps are characterized depending on the specific 
organization of the genes in the system as belonging to five families:  ATP-Binding 
Casette (ABC) [93], Major Facilitator Superfamily (MFS) [94, 95], Multidrug and Toxic 
compound Extrusion (MATE) [96], Resistance-Nodulation-cell Division (RND) [97], and 
Small Multidrug Resistance (SMR) [98].  Whole genome sequencing of Elizabethkingia 




has been no biochemical confirmation of these systems functioning as drug efflux pumps 
in the Elizabethkingia. 
 
Despite the well-established inability of vancomycin to inhibit Gram-negative 
bacilli in vitro [99], the drug has been used clinically to treat serious Elizabethkingia 
infections with variable success. Based on Kirby-Bauer disk diffusion susceptibility data, 
George et al. [100] used vancomycin to treat six infants with Elizabethkingia infections 
and three of these infants died. Plotkin and McKitrick [55] also described a case of 
neonatal meningitis that was treated successfully with vancomycin. More favorable 
results were reported amongst Elizabethkingia infections in non-neonatal patients, where 
all three cases treated exclusively with vancomycin survived [48, 54, 101]. When used to 
treat Elizabethkingia infections vancomycin is more frequently used in combination, with 
rifampin and ciprofloxacin being the most common partners. Like treatment with 
vancomycin alone, combination therapy seems to show some clinical efficacy, with 16 
out of 20 reported cases surviving when treated with vancomycin combination therapies 
[49, 89, 102-104]. It should be noted, however, that any assessment of vancomycin as a 
stand-alone treatment or in combination is complicated by the small number of reported 
cases along with potential bias among those cases that are reported. 
 
The assessment of vancomycin susceptibility in Elizabethkingia is complicated by 
the lack of uniform standards for interpreting the results of Kirby-Bauer or minimum 
inhibitory concentration (MIC) assays [105]. As a result, both Kirby-Bauer disk diffusion 




and Laboratory Standards Institute (CLSI) for Staphylococcus aureus, which in turn has 
led to contradictory susceptibility results.  In 1971, for example, the first report 
suggesting that the Kirby-Bauer assay significantly underestimated the resistance of 
Elizabethkingia to vancomycin was published by Aber et al. [86], and several other 
reports confirming this discrepancy followed [105-107].   Even with these reports, 
vancomycin remains a drug of choice to treat Elizabethkingia infections as recently as 
2018 [102]. 
 
1.2 Companion and food animals as a source of antimicrobial-resistant organisms 
It has been well documented that both food and companion animals may serve as 
reservoirs for antibiotic-resistant bacterial pathogens [26-34].  Matyi et al. [26] isolated a 
methicillin-resistant S. aureus (MRSA) strain from a dairy cow undergoing antibiotic 
treatment that was virtually identical to a clinical MRSA strain isolated from a human at 
the genomic level. Voss et al. [27] demonstrated a much greater prevalence rate for 
MRSA carriage among pig farmers and Lozano et al. [28] reported carriage of identical 
MRSA clones by pigs and pig farmers.  Bates et al. [29] isolated vancomycin-resistant 
Enterococcus faecium strains from pigs that shared the same ribotype as isolates from 
hospital patients.  With regard to companion animals, Guardabassi et al. [30] detected 
similar antibiotic-resistant clones of Staphylococcus intermedius in humans and dogs, 
while Damborg et al. [33] detected quinolone-resistant Campylobacter jejuni with 
identical pulsed-field gel electrophoresis signatures in a young patient and her dog. In 




bacteremia, and it is possible that farm and/or companion animals can also act as 
reservoirs for Elizabethkingia that cause infections. 
 
1.3 Vancomycin 
1.3.1 History of vancomycin 
Vancomycin was isolated from Streptomyces orientalis in 1955 and quickly noted 
for the strong inhibitory effect exerted on Gram-positive cocci [99]. Preliminary 
investigation suggested that vancomycin functioned as an inhibitor of RNA synthesis in 
S. aureus [108], however subsequent investigations rapidly identified peptidoglycan 
biosynthesis as the primary target of vancomycin [109, 110]. It is now well established 
that vancomycin inhibits the transpeptidation reaction linking new peptidoglycan 
polymers to the existing cell wall by binding the terminal D-Ala-D-Ala residues on the 
pentapeptide stem [111-114].  Fairbrother and Williams [99] tested the activity of 
vancomycin against 1,350 bacterial isolates by Kirby-Bauer disk diffusion assay and 
noted that while all of the Gram-positive organisms tested were inhibited by vancomycin, 
it was only marginally effective against Gram-negative cocci, and completely ineffective 
against Gram-negative bacilli.  
 
The cell envelope of Gram-negative organisms includes an outer membrane (OM) 
which consists of an outer lipopolysaccharide leaflet over an inner phospholipid leaflet 
which hinders penetration of many antimicrobials into the periplasmic space [115].  
Embedded within the OM are outer membrane porins (OMPs) which function as channels 




excluding larger molecules such as vancomycin (~1446 Daltons) [116-118].  E. coli 
mutants with mutations in OMPs or porin assembly that lead to increased OM 
permeability demonstrate significant increases in susceptibility to large antimicrobials, 
including vancomycin [119-121]. Krishnamoorthy et al. [122] demonstrated that 
vancomycin susceptibility was increased in E. coli constructs overexpressing a modified 
fhuA OMP lacking the N-terminal plug domain, allowing free diffusion of hydrophilic 
substances across the OM.  They further demonstrated that disruption of tolC, which 
produces a periplasmic channel that works in concert with instrinsic antimicrobial efflux 
pumps, led to no discernable changes in vancomycin MICs.  These results suggest that 
vancomycin susceptibility in E. coli is governed OM permeability alone.  
 
In addition, Zhou et al. [123] found that both nitrofurantoin and trimethoprim 
displayed synergy with vancomycin against E. coli growth.  These authors also 
hypothesized that since other cell wall biosynthesis inhibitors demonstrated antagonism 
with nitrofurantoin or trimethoprim, that vancomycin may be acting on pathways other 
than peptidoglycan biosynthesis. Intriguingly, Kang et al. [124] reported that the 
vancomycin MIC of an E. coli mutant defective in the synthesis of thymidine through the 
deletion of the deoxycytidine deaminase gene dcd decreased 8-fold when compared to the 
parent strain.  This increase in vancomycin susceptibility was further enhanced by the 
addition of cytidine but could be reversed by the addition of thymine to the growth 
medium, and the authors speculate that small amounts of vancomycin may penetrate to 
the cytoplasm causing oxidative damage to DNA [124, 125].  These findings raise the 




biosynthesis inhibition and underscores the importance of understanding how 
vancomycin interacts with Gram-negative cells such as Elizabethkingia. 
 
1.3.2 Transcriptional profiling of cells challenged with vancomycin 
While to the best of our knowledge no transcriptional profiling has been done for 
Gram-negative organisms challenged with vancomycin, the transcriptional response of 
Gram-positive cells has been studied.  Vancomycin challenge significantly upregulates 
the two component sensor system vraRS, which functions as the primary sensor of cell 
wall stress in Gram-positive organisms [126].  Other genes that are found to be 
significantly upregulated during vancomycin exposure include components of the 
phosphotransferase system, members of the proline/glycine – betaine transport system, 
amino acid biosynthesis pathways including glutamate, cysteine, histidine, lysine, 
threonine, serine, and valine/isoleucine [127].  Genes encoding putative amino acid and 
oligopeptide transporters and the Krebs cycle components citB, citC, and citZ were also 
significantly upregulated [127-130].  Penicillin binding protein (PBP) 2 was found to be 
significantly upregulated in multiple studies [127-130], while other components the cell 
wall stress response stimulon were more variable [127-130].  Genes involved in cell 
division, replication, tRNA modification enzymes, autolysins, hemagglutinin proteins, 






1.4 Cell wall stress response in Gram-negative organisms 
Gram-negative organisms are surrounded by a complex cellular envelope 
consisting of the asymmetric outer membrane, a thin peptidoglycan layer, and the inner 
membrane [131].  Some organisms also produce a polysaccharide capsule which covers 
the outer membrane and functions to protect the cell from harmful conditions 
encountered in the environment.  The integrity of this envelope is critical to the survival 
of cells in the face of changing environmental factors, stressors, predation, and potential 
antimicrobial challenge.  Of particular importance is the integrity of the peptidoglycan 
layer, as this is the primary structure that helps cells to resist osmotic pressure, and 
defines cell shape.  Unlike the vraRS two component sensor system in Gram-positive 
bacteria [126] there is no known single stress response sensor system in Gram-negative 
cells with the primary function of detecting cell wall damage [132].  Instead, Gram-
negative organisms have five main cell envelope stress sensor systems: (Cpx) [133, 134], 
bacterial adaptive response (Bae) [135], regulator of capsule synthesis (Rcs) [136], Rse, 
and phage shock protein (Psp) systems.  Of these systems, the Cpx and Rcs systems 
appear to be the most responsive to peptidoglycan-associated stresses [133, 136].  The 
Cpx system is a classic two component sensor system, with cpxA encoding for the 
histidine sensor kinase component while cpxR encodes the response regulator [134, 137].  
This system has two accessory genes: cpxP encodes a negative regulator of the cpxRA 
system, while nlpE encodes an outer membrane lipoprotein that aids in the detection of 
protein sorting and membrane associated protein defects [134].  This system is 
considered the primary cell envelope quality control system as CpxA and NlpE function 




space [133, 137].  CpxR is known to induce the production and transport into the 
periplasmic space of chaperones and proteases [133, 134, 137].  The Rcs system is more 
complex, with rcsC encoding the membrane associated sensor histidine kinase and rcsB 
encoding the primary response regulator [136, 138].  Activation of RcsB does not occur 
directly from RcsC, but is rather transduced through another membrane bound protein, 
RcsD [138, 139].  Both RcsC and RcsD are bound by another accessory protein IgaA 
which keeps these sensors in an inactive state and blocks the phosphorylation of RcsB 
[138-140].  A second sensor, RcsF, is located in the outer membrane and serves as the 
initiator of the signal cascade by binding to IgaA, which in turn releases RcsC and RcsD, 
which can then activate RcsB [139, 140].  RcsB can function as a homodimer, or it can 
dimerize with RcsA to form a heterodimer that is known to activate the expression of 
genes involved in the synthesis of capsular polysaccharides [138].  Other genes regulated 
by the Rcs system include genes for the production of lipopolysaccharide, flagella, 
fimbriae, and other cell wall structures, along with genes associated with virulence [140].  
The Rcs system is thought to be the main cell wall stress detection system, and is the only 
response system that was consistently activated by β-lactam antibiotics or the destruction 
of the cell wall by lysozyme [136].  The Cpx and Bae systems were activated when the 
main penicillin binding proteins, PBP1a and 1b, along with PBP2, were inhibited by a 
combination of β-lactam antibiotics, but only under specific conditions [135].  There is 
evidence that activation of the Rcs system may be dependent in part on activation of the 
Cpx response system, however this has not been investigated in detail [135].  
Unfortunately, which of these systems, if any, responds to cell wall damage caused by 





1.5 Transcriptional profiling of Elizabethkingia 
To the best of our knowledge the transcriptional profiling of Elizabethkingia is 
limited to two studies [75, 141].  Li et al. [75] investigated the stress response of 
Elizabethkingia following challenge with a sub-lethal concentration of hydrogen peroxide 
and found significant increases in the expression of iron uptake and iron utilization 
proteins, while several putative efflux systems were significantly downregulated [75].  
Chen et al. [141] evaluated the transcriptional response of Elizabethkingia grown in high 
and low iron conditions to simulate conditions encountered by these organisms in the 
midgut of a mosquito during blood feeding.  The authors reported that genes related to 
the electron transport chain, the TCA cycle, and iron-sulfur cluster protein synthesis were 
significantly upregulated, while iron uptake, genes related to translation, and amino acid 
metabolism were significantly downregulated [141]. 
 
1.6 Goals of the present studies 
i. Characterization of equine-associated Elizabethkingia isolates.  
Elizabethkingia have been isolated from companion animals [14], and it is 
known that pathogens can be transferred between these animals and humans 
[142].  Therefore, the objective of this work was to investigate the 
antimicrobial susceptibility profiles and phylogenetic relationships with 
known human pathogenic isolates of two E. anophelis horse isolates obtained 
from the local veterinary teaching hospital. This work has been published in 





ii. Evaluation of the impact of vancomycin on Elizabethkingia.  Vancomycin 
remains in use as an antibiotic used to treat Elizabethkingia infections, and the 
assessment of the efficacy of vancomycin treatment in the Elizabethkingia is 
complicated by the difficulties in determining susceptibility to this drug in 
confirmed Elizabethkingia species [105, 143].  This is further exacerbated by 
the lack of defined breakpoints for delineating susceptibility or resistance to 
vancomycin [105].  Therefore, the objective of this project was to evaluate the 
physiological impact of vancomycin on a collection of 21 characterized strains 
from six currently known genomospecies. 
 
iii. Elucidation of the transcriptomic response to vancomycin in 
Elizabethkingia anophelis R26.  We wanted to determine how vancomycin 
affects the transcriptome of Elizabethkingia.  Due to the cell wall active nature 
of vancomycin, combined with the importance of outer membrane 
permeability in resisting the action of vancomycin I hypothesized that genes 
involved with cell wall stress, outer membrane permeability, and generalized 
stress response would be significantly altered in vancomycin-challenged cells.  
In order to test this hypothesis, I conducted RNASeq on Elizabethkingia 
anophelis R26T challenged with vancomycin, with the goal of using RNASeq 
to better understand how these organisms respond to vancomycin, and to 






iv. Isolation and characterization of E. anophelis R26 and E. ursingii G4122 
isolates demonstrating vancomycin resistance.  As described in project ii 
above, I evaluated the physiological aspects of vancomycin challenge against 
Elizabethkingia.  This study revealed that cultures challenged by vancomycin 
experienced an initial decrease in viable cell counts, while light microscopy 
confirmed that this decrease was the result of cell death.  However, this 
decrease was followed by a rapid rebound to cell densities comparable to the 
unchallenged control cultures. This raised the prospect that mutants 
demonstrating increased resistance to vancomycin arose in normal laboratory 
media containing growth inhibitory concentrations of vancomycin.  In this 
project I aimed to isolate mutants demonstrating vancomycin resistance by 
single step selection and to characterize the genomic mutations underlying this 









MATERIALS AND METHODS 
2.1 Strains and working conditions 
A list of all bacterial isolates used in this dissertation can be found in Table 1.  All 
working stocks were maintained on heart infusion agar (HIA; Remel, San Diego, CA, 
USA) supplemented with 5% defibrinated rabbit blood (Hemostat Laboratories, Dixon, 
CA, USA).  Overnight cultures were prepared by inoculating a single colony into heart 
infusion (HIB) or Mueller-Hinton (MHB) broth, followed by overnight incubation (37°C, 
200 rpm).   
 
2.2 Antimicrobial susceptibility testing 
All antimicrobial susceptibility testing was performed following standardized 
protocols developed by the CLSI [144].  Relevant antimicrobial solvent controls were 
tested ensure that there was no growth inhibition caused by the solvent itself. 
2.2.1 Minimal inhibitory/bactericidal concentration assays 
For broth macrodilution assays master mixes (2 X the final desired concentration) 
were prepared for each concentration to be tested by adding an appropriate volume of 




Table 1. Sources and dates of isolation when available of bacterial isolates in this study. 
Isolates in bold were chosen for whole genome sequencing. 
 
Isolate Species Source and Date Reference 
R26 anophelis Anopheles gambiae G3, 2006 [7] 
R26-VER1 anophelis Selected from R26 This study 
R26-VER2 anophelis Selected from R26 This study 
R26-VER3 anophelis Selected from R26 This study 
422 anophelis Blood; Florida, USA; 1950 [145] 
3375 anophelis Spinal fluid and throat culture; 
South Carolina, USA; 1957 
[145] 
E6809 anophelis Blood; California, USA; 1979 [145] 
F3201 anophelis Spinal fluid; Kuwait; 1982 [145] 
F3543 anophelis Spinal fluid; Florida, USA; 1982 [145] 
OSUVM-1 anophelis Equine Endoscope; Oklahoma, 
USA, 2016 
[74] 
OSUVM-2 anophelis Equine guttural pouch aspirate; 
Oklahoma, USA; 2016 
[74] 
ATCC 33958 bruuniana Contaminated commercial enzyme 
preparation; California, USA; 1982 
[146] 
G0146 bruuniana Blood culture; Margate, England [145] 
G0153 bruuniana Urine; Dublin, Ireland [145] 
G4075 bruuniana Blood culture; Strasbourg, France; 
1978 
[145] 
KC1913 meningoseptica Spinal fluid; Massachusetts, USA; 
1949 
[145] 
G4120 meningoseptica Conjunctivitis; Nottingham, 
England 
[145] 
G4076 meningoseptica Urine; St. Brieuc, France; 1983 [145] 
G4071 miricola Tracheal exudate; Strasbourg, 
France; 1978 
[145] 
G4074 miricola Suction water; Reading, England [145] 
G4121 miricola Water; Goteborg, Sweden; 1982 [145] 
G4070 occulta Sputum; Melbourne, Australia; 
1977 
[145] 
G4122 ursingii Soil; Odense, Denmark; 1964 [6] 
G4122-VRS6 ursingii Selected from G4122 This study 
G4122-VRS7 ursingii Selected from G4122 This study 
G4122-VRS8 ursingii Selected from G4122 This study 
G4122-VRS9 ursingii Selected from G4122 This study 
G4122-VRS10 ursingii Selected from G4122 This study 







maximum speed for at least 5 sec, and 1 ml was then transferred to a sterile screw-capped 
tube.  Overnight cultures were then diluted to an optical density at 600nm (OD600nm) = 
0.01, and 1 ml of diluted culture was added to each tube.  Typical final antimicrobial 
concentrations tested ranged from 256 mg/L to 0.25 mg/L following the addition of 
culture.  Bleach and ethanol minimum inhibitory concentrations (MICs) were performed 
following this method, and final bleach concentrations ranged from 0.08% to 10% (v/v) 
with 0.01% increments from 0.08% to 1.5%, along with 2%, 5%, and 10%.  Final ethanol 
concentrations ranged from 1% (v/v) to 12% in 1% increments.  These tubes were then 
securely capped and incubated for 24 h without shaking at 37°C.  The MIC was 
determined to be the lowest antimicrobial concentration with no visible turbidity 
following incubation. 
 
Microdilution MIC assays were performed on 96 well microtiter plates by adding 
100 µl sterile MHB to the first 11 columns of the 12 column microtiter plate.  One-
hundred µl of the appropriate antimicrobial was then added to columns 11 and 12.  The 
solution in column 11 was mixed by tituration, and 100 µl was transferred to column 10.  
This solution was mixed by tituration, and 100 µl was transferred to column 9, and these 
steps repeated until column 2.  Following tituration 100 µl was removed from column 2 
and discarded.  This yielded 2-fold serial dilutions at 2 X the desired final concentration.  
Overnight cultures were then diluted to an OD600nm = 0.01, and 100 µl of diluted culture 
was added to each well.  Plates were then incubated for 24 h at 37°C without shaking, 
and the MIC was determined as described above.  Minimum bactericidal concentrations 




antimicrobial concentration demonstrating visible growth, and repeating until the highest 
tested concentration onto drug-free MHA.  Plates were then incubated for 24 h at 37°C, 
and the MBC determined as the lowest concentration demonstrating no visible growth. 
 
2.3 Characterization of equine-associated Elizabethkingia isolates 
2.3.1 Isolate Identification 
For bacterial identification, fresh colonies grown on tryptic soy agar containing 
5% sheep blood were applied to a spot on the MALDI-TOF MS target plate and overlaid 
with freshly made matrix solution containing 70% formic acid and α-cyano-4-
hydroxycinnamic acid following the manufacturer’s recommendations.  Bacterial 
identification was carried out using a Microflex LT MALDI-TOF mass spectrometer 
using default settings.  Bacterial peptide spectra were collected using FlexControl 
software in positive linear mode with a mass range from 2 to 20 kDa and a laser 
frequency of 60 Hz (IS1 - 20 kV; IS2 - 18 kV; lens - 6 kV; extraction delay time of 100 
ns) in automatic mode by accumulating a maximum of 240 profiles (40 laser shots from 
six different positions of the target spot).  Microbial peptide mass spectra were then 
analyzed using the Biotyper RTC software version 3.1 using the default settings and 
database version 4.0.0.1.  Both OSUVM-1 and OSUVM-2 were identified by MALDI-
TOF MS as E. meningoseptica.   This is consistent with the known insufficiency of 
MALDI-TOF MS default databases to correctly identify certain Flavobacteriacae, 






2.3.2 Genomic Sequencing and Analysis 
Genomic DNA was isolated from 3 ml overnight cultures of OSUVM-1 and 
OSUVM-2 grown in HIB as described above using Qiagen Genomic-tip 100/g columns 
following the manufacturer’s protocol.  The resulting DNA samples were sent to 
Molecular Research LP where library preparation was performed using the Nextera DNA 
sample preparation kit.  Genomic DNA was then sequenced using PacBio SMRT 
sequencing and Illumina MiSeq systems and assembled using SeqMan NGen® version 
12.0 with paired end sequencing parameters on the default settings.  The resulting 
assemblies were annotated using the Rapid Annotations Using Subsystems Technology 
(RAST) server [150-152] and the Prokaryote Genome Annotation Pipeline [153]. Both 
genomes were further analyzed using the nucleotide and protein Basic Local Alignment 
Search Tool (BLAST) [154, 155]. The draft genome sequences can be found under 
bioproject PRJNA397081. OSUVM-1 and OSUVM-2 are represented by biosamples 
SAMN08100548 and SAMN08100549 and nucleotide accession numbers 
PJMA00000000 and PJLZ00000000, respectively. 
  
The OSUVM-1 and OSUVM-2 genomes were shared with the Special 
Bacteriology Reference Laboratory (SBRL) at the Centers for Disease Control and 
Prevention (CDC), where they were compared to the genomes of E. anophelis isolates 
derived from human clinical specimens which were obtained after the 2016 Wisconsin 
Elizabethkingia outbreak [4].  These genomes had been sequenced from cultures grown 
at 35°C on heart infusion agar supplemented with 5% rabbit blood.   DNA was extracted 




DNA and RNA Purification Kit, according to the manufacturer’s instructions.  Libraries 
were prepared using the NEBNext Ultra DNA library prep kit (, then sequencing was 
done with an Illumina MiSeq instrument using a 2x250 paired-end protocol as described 
previously [37].  The de Bruijn graph de novo assembler in CLC Genomics Workbench 
version 9.0. was used on reads trimmed with a quality limit of 0.02 to produce draft 
genomes.   Ambiguous nucleotides (N’s) in the resulting contigs were resolved using read 
alignments, and contigs were split wherever N’s could not be resolved.  The accession 
numbers of these strains are NWMM00000000, NWMI00000000, and NWMH00000000.  
Genomes were aligned and single nucleotide polymorphism (SNP) trees produced using 
HarvestTools [156], and exported Newick files were edited using MEGA v6 [157]. 
 
2.4 Evaluation of the impact of vancomycin on Elizabethkingia  
2.4.1 Vancomycin survival assay 
Overnight cultures were diluted in MHB to an OD600nm = 0.01, and 25 mL was 
aliquoted into 4 50 mL flasks containing no addition, and 1 X the MIC, 1.5 X the MIC, 
and 1 X the MBC of vancomycin. These flasks were incubated (200 rpm, 37°C) and the 
OD600nm was measured over time. Colony forming units per 1 ml (CFUs) were also 
estimated by plating 10 μl of culture serial dilutions on drug-free Mueller-Hinton agar 
(MHA), followed by overnight incubation (37°C). 
 
2.4.2 Antimicrobial and synergism testing 
Synergy assays were performed for combinations of vancomycin + ciprofloxacin 




fractional inhibitory concentration index (FICI) using the same criteria as Di Pentima et 
al [158].  Gradient plates were prepared as described previously [159]: 40 ml of drug free 
MHA was added to 90 X 90 mm square Petri plates.  Plates were elevated 6 mm on one 
end and allowed to cool overnight.  Subsequently, each plate was laid flat, 40 ml of MHA 
supplemented with the appropriate antibiotic concentration was added, and the plates 
were dried open faced for 4 h.  Overnight cultures of each isolate were diluted in MHB to 
an OD600nm = 0.1, spread onto each plate with a sterile cotton swab, and all plates were 
incubated for 48 h (37°C).  The distance of confluent growth (mm) of three biological 
replicates for each isolate was measured and compared by one-way ANOVA followed by 
Tukey-Kramer post hoc testing in JMP 14Pro. 
 
2.4.3 Scanning electron microscopy 
Cells were prepared for SEM imaging by diluting a standard overnight culture to 
an OD600nm = 0.01 in MHB followed by incubation to mid-exponential phase (OD600nm = 
0.70). The cells were then challenged with 12 mg/L vancomycin after which the cells 
were collected by centrifugation (5000 X g, 5 min). The pelleted cells were re-suspended 
in 2% glutaraldehyde solution in sodium cacodylate buffer for 20 min, followed by 
fixation to a glass coverslip coated in poly-L-lysine for 1 h, and washed 3 times in 
sodium cacodylate buffer (15 min per wash). Cells were subsequently fixed in 1% 
osmium tetroxide for 1 h, washed 3 times with sodium cacodylate (15 min per wash), and 
progressively dehydrated under increasing concentrations of ethanol (50%, 70%, 90%, 
95%, and 3 x 100%; 15 min per treatment). Final solvent substitution was carried out by 




sputter coated with a gold-palladium mixture and visualized utilizing a FEI Quanta 600 
field emission gun Environmental SEM. 
 
Cell sizes were determined by imaging five random fields at 15,000 X 
magnification and length and width measurements taken using the acquisition software 
for each discreet cell in the field.  As the distributions of measured cell sizes differed 
significantly from normal (Shaprio-Wilke test for normality, P < 0.01 for all 
comparisons) cell sizes were compared using the Mann-Whitney U-test in JMP 14Pro. 
 
2.4.4 Live cell microscopy 
Overnight cultures were diluted in MHB to an OD600nm = 0.01 and incubated for 3 
h (37°C, 200 rpm).  Following incubation, vancomycin was added to a final 
concentration of 1.5 X the MIC for each isolate and a 1 µl aliquot was transferred to a 
sterile 1% agar pad at room temperature for visualization.  Challenged cultures were then 
incubated for 4 h (37°C, 200 rpm), with 1 µl aliquots removed for imaging at 2 h and 4 h 
post challenge.  Phase contrast images were collected on a NikonNi-E epifluorescent 
microscope equipped with a 100X/1.45 NA objective (Nikon), Zyla 4.2 plus cooled 
sCMOS camera (Andor), and NIS Elements software (Nikon).  Three biological 





2.5 Elucidation of the transcriptomic response to vancomycin in Elizabethkingia 
anophelis R26 
2.5.1 Sample preparation and RNA extraction 
Overnight cultures for three biological replicates were diluted in 25 ml MHB to 
an OD600nm = 0.01.  Diluted cultures were transferred to 50 ml growth flasks and 
incubated with shaking (37°C, 200 rpm) until mid-exponential phase (OD600nm = 0.7).  
Two 5 ml aliquots of mid-exponential phase cells were then transferred to overnight 
culture tubes where the treatment tube was challenged with 12 mg/L vancomycin (1.5 X 
the MIC), while the control tube received an equal amount of autoclaved diH2O, and 
incubated with shaking for 30 min.  Following incubation, RNA was stabilized in 
RNAProtect for 5 min at room temperature, and RNA was extracted using the RNeasy 
minikit following the manufacturer’s protocol.  Ribosomal RNAs were removed from 
each sample using the Ribo-Zero kit following the manufacturer’s instructions.  Libraries 
were then prepared for sequencing using the Illumina TruSeq Stranded mRNA Sample 
Preparation Kit following the manufacturer’s protocol and the quality verified using an 
Agilent Technologies 2100 Bioanalyzer.  Libraries were then sequenced at the Oklahoma 
State University Core Facility using an Illumina NextSeq sequencer. 
 
2.5.2 Data analysis 
All analysis was conducted on the Galaxy server, where sequencing data was 
initially subjected to adaptor sequence trimming and quality control using the 
Trimmomatic and Fast QC packages, respectively.  Paired reads were then mapped to the 




feature using the featureCount package.  Finally, feature counts were normalized and 
compared between control and treatment groups using the edgeR package.  Genes were 
considered to be altered if there was a greater than 2-fold change and the false discovery 
rate was below 0.05. 
 
2.6 Isolation and characterization of E. anophelis R26 and E. ursingii G4122 isolates 
demonstrating vancomycin resistance.   
2.6.1 Selection of vancomycin-resistant mutants 
Overnight HIB cultures were ten-fold serially diluted and 100 μl was plated on 
HIA plates supplemented with increasing concentrations of vancomycin ranging from 2 – 
20 mg/L. Following overnight incubation (37°C), single isolated colonies were picked, 
and passaged 3 times on drug free HIA, before making HIB overnight cultures and 20% 
glycerol freezer stocks. Vancomycin MICs and MBCs for each isolate were determined 
by broth microdilution following standard CLSI guidelines [144]. 
 
2.6.2 Whole genome sequencing, mapping, annotation, and analysis of vancomycin-
resistant mutants 
Genomic DNA from E. anophelis R26 along with vancomycin-resistant mutants 
R26-VSR1, R26-VSR2, and R26-VSR3, along with E. ursingii vancomycin-resistant 
mutants G4122-VR6 and G4122-VR10 was extracted from 3 ml overnight cultures and 
sequenced as described previously [74]. Briefly, raw reads were trimmed to remove 
adapter sequences and for quality control using a quality threshold of 0.02 and 0 




reference genome of each parent strain using the default options and the consensus 
sequence for each isolate extracted. All reported mutations were verified by inspection of 
the raw reads. All trimming and mapping steps were performed using CLC Genomics 
Workbench v11.0.1. Consensus sequences were annotated using the Rapid Annotations 
Using Subsystems Technology (RAST) server [150-152]. Regulatory elements were 
predicted using the BPROM program [160] while the identity and putative functional 
domains of hypothetical proteins were investigated using nucleotide and protein Basic 
Local Alignment Search Tool (BLAST) [154, 155]. 
 
2.6.3 Quantitative polymerase chain reaction analysis 
A 1% (v/v) inoculum of cells from standard E. anophelis R26, R26-VSR3, E. 
ursingii G4122, and G4122-VR6 overnight cultures were added to 3 ml MHB and 
incubated to mid-exponential phase, at which point cells were challenged with 1.5 X the 
vancomycin MIC for 2 h, and harvested by centrifugation (5000 X g, 5 min).  Cells were 
lysed in 1 ml Trizol, followed by nucleic acid extraction in chloroform.  Total RNA was 
precipitated from the aqueous layer by the addition of 0.5 volume isopropanol followed 
by centrifugation (12,000 X g, 5 min, 4°C).  The resulting RNA was then washed with 
ice cold 70% (v/v) ethanol, dried at room temperature for 30 min, and resuspended in 
ultrapure diH2O.  RNA extractions were screened for DNA contamination by PCR using 
primers targeting the RNA polymerase β subunit (Table 2) and first strand cDNA 
synthesis was performed using the Agilent First Strand cDNA Synthesis Kit following 
the manufacturer’s protocol using random hexamer primers.  Gene specific amplification 







Table 2.  Primers, target gene, and sequence of qPCR primers.  
Primer Name Isolate Gene Target Primer Sequence 
mpF 






















a LightCycler 96 instrument using SYBR-Green.  Triplicate biological and technical 
replicates were used for all comparisons.  Expression change was assessed using rpoB as 
the standard housekeeping gene for all comparisons.  All expression data was found to be 
normally distributed (Shaprio-Wilke test for normality, P > 0.05 for all comparisons), and 
all statistical analyses were carried out using parametric statistics in JMP 14Pro.  ΔΔCt 
values were compared by Student’s t-test, with mean ΔΔCt values transformed to fold 








RESULTS AND DISCUSSION 
3.1 Characterization of equine associated Elizabethkingia isolates  
Despite exhaustive investigation, the source(s) of the 2015 – 2016 Midwestern US 
E. anophelis outbreak remain elusive [4].  This outbreak is notable for several reasons, 
including the large number of community-acquired cases, and the absence of E. anophelis 
from sink taps and other water storage sources, which are frequently the sources for 
Elizabethkingia outbreaks [13, 19, 20, 34, 161, 162].  Both companion and food animals 
may serve as reservoirs for antibiotic-resistant bacterial pathogens [26-34], and the 
transmission of multiply-antibiotic resistant organisms between humans and these 
animals has been documented [142, 163, 164].  While there is no evidence that the 2015 
– 2016 E. anophelis outbreak was one of these cases, instances of Elizabethkingia 
infection have been reported in several animal species [14-17].  Hu et al. [15] further 
reported that an E. miricola isolate responsible for a large outbreak in frogs was closely 
related to E. miricola isolated from humans.  In 2016 the Oklahoma Animal Disease 
Diagnostic Laboratory isolated two confirmed E. anophelis strains that were associated 
with horses [74], and the objective of this project was to evaluate the genomic 




3.1.1 Sequencing and mass spectrometry analysis 
The assembly of OSUVM-1 sequence data produced 7 contigs and a genome of 
4,153,767 bp (%GC = 35.5).  OSUVM-1 contained 3,850 putative coding sequences 
(CDS), of which 3,777 were protein CDS. RAST annotation assigned function to 2,421 
(64%) predicted protein CDS and identified 75 rRNA and tRNA CDS.  OSUVM-2 
sequences were assembled into 10 contigs to produce a genome of 4,109,384 bp (%GC = 
35.5).  OSUVM-2 contained 3,814 CDS, of which 3,750 were protein CDS. RAST 
annotation assigned function to 2,404 (64%) predicted protein CDS and identified 64 
rRNA and tRNA CDS.  
 
Bacterial identification using MALDI-TOF indicated that both OSUVM-1 and 
OSUVM-2 were members of the Elizabethkingia genus.  The Elizabethkingia are 
nonmotile [27] and RAST analysis of the draft genomes of OSUVM-1 and OSUVM-2 
revealed no features supporting motility and chemotaxis.  The subsystem feature count in 
both strains were identical for 16 of 25 subsystems identified in the draft genomes which 
differed in the feature count of the following subsystems: cell wall and capsule; 
virulence, disease, and defense; miscellaneous; membrane transport; iron acquisition and 
metabolism; protein metabolism; stress response; metabolism of aromatic compounds; 
and phages, prophages, and transposable elements (Table 3).  This last finding is 
consistent with our expectation that the loci carried by mobile genetic elements will be 
better represented in a complete genome than a draft genome, since a draft genome will 




Table 3.  Distribution in coding sequence function as identified by RAST.  Subsystems 
with differences in the number of coding sequences in the two strains are highlighted in 
bold. 
Subsystem 




Cofactors, vitamins, prosthetic groups, 
pigments 
201 201 
Cell wall and capsule 78 77 
Virulence, disease, and defense 93 89 
Potassium metabolism 12 12 
Miscellaneous 28 27 
Phages, prophages, and 
transposable elements 
8 7 
Membrane transport 66 63 
Iron acquisition and metabolism 25 24 
RNA metabolism 121 121 
Nucleosides and nucleotides 64 64 
Protein metabolism 203 225 
Cell division and cell cycle 29 29 
Regulation and cell signaling 48 48 
Secondary metabolism 8 8 
DNA metabolism 95 95 
Fatty acids, lipids, and isoprenoids 101 101 
Nitrogen metabolism 12 12 
Dormancy and sporulation 4 4 
Respiration 66 66 
Stress response 70 71 
Metabolism of aromatic compounds 19 18 
Amino acids and derivatives 325 325 
Sulfur metabolism 15 15 
Phosphorus metabolism 21 21 





number of copies of the transposon in the genome) while a complete genome will allow 
each gene in multiple copies to be identified. 
 
3.1.2 Core genome and phylogenetic analysis 
Nucleotide BLAST and phylogenetic analysis of the core genome of both isolates 
revealed that both strains were E. anophelis.  Both OSUVM-1 and OSUVM-2 are part of 
a clade of strains resembling E. anophelis strain JM-87 [5, 30], which was isolated from 
Zea mays stem tissue and initially described as the type strain of Elizabethkingia 
endophytica before whole genome sequence analysis revealed it to belonged to the E. 
anophelis species (Figure 2) [5, 7].  Using the HarvestTools v1.1.2 module ParSNP, we 
determined that both OSUVM-1 and OSUVM-2 are closely related to E. 
anophelis isolates derived from human clinical specimens in Minnesota, Illinois, and 
Tennessee (Figure 2).  A second analysis limited to OSUVM-1, OSUVM-2, and the three 
human clinical isolates, revealed an 87% core genome among the five strains.  Once 
ambiguous nucleotides were excluded only 198 SNP positions were located, scattered 
throughout the core genome of the five strains, and OSUVM-1 and OSUVM-2 differed 
by only 6 SNPs in the core genome, suggesting that OSUVM-1 and OSUVM-2 are 
clonal. 
 
These results indicate that these five strains are highly related and that the two 
OSUVM isolates share commonalities with strains isolated from human Elizabethkingia 





Figure 2. Core genome single nucleotide polymorphism tree showing the position of 
OSUVM-1 and OSUVM-2 compared to E. anophelis strains reported by Nicholson et 
al.[29]. Type strains are denoted by a superscript T, and the location of the isolates from 
this study is denoted by a bracket.  Reprinted from Johnson et al. [74] under Creative 




miricola strain responsible for a contagious disease resulting in black-spotted frog losses 
at farms in China and was highly related to an E. miricola isolate isolated from a human 
case in China.  Collectively these findings suggest that Elizabethkingia are not host-
specific, which raises the possibility that Elizabethkingia might have the potential to 
move between humans and animals in a similar manner to known zoonotic pathogens. 
 
3.1.3 β-lactamases 
Genomic analysis of Elizabethkingia spp. consistently identifies multiple β-
lactamases, including three characterized β-lactamases [72, 73, 165], along with a 
varying number of putative β-lactamases [4, 5, 9, 10, 12, 37, 76, 77, 79-81].  The 19 
putative β-lactamase CDS in both OSUVM-1 and OSUVM-2 included the previously 
characterized class A serine β-lactamase (SBL) blaCME-1 [73], and metallo-β-lactamases 
(MBL) class B1 blaB14 [165] and class B3 blaGOB18 [72].  Of the remaining 16 putative β-
lactamases, one is similar to the previously characterized class A SBL blaCIA-1 from 
Chryseobacterium indologenes (67% amino acid identity) [166], 11 are similar to class C 
SBLs, and the remaining 7 were classified as putative MBLs. 
 
3.1.4 Multidrug efflux pumps 
Efflux pumps are a key component of the intrinsic antibiotic-resistance 
mechanism of many bacteria and function by transporting antibiotics from within the cell 
to the outside [90-92].  Genomic annotation of all Elizabethkingia spp. reveals the 
presence of several drug efflux pumps, yet none of these transporters has been 




revealed 32 CDS related to antibiotic efflux in both OSUVM-1 and OSUVM-2: 18 of the 
32 CDS (56%) were identified by RAST analysis as components of RND efflux operons, 
12 CDS (38%) as components of MFS operons, while the remaining 2 CDS (6%) were 
identified as MATE efflux pumps.  
 
We are interested in the RND pumps in the draft genomes of OSUVM-1 and 
OSUVM-2 since RND efflux pumps can be a major factor contributing to clinically-
relevant resistance to certain antibiotics in Gram-negative organisms [90].  Tripartite 
RND efflux pumps consist of an inner membrane pump attached to an outer membrane 
porin by way of a periplasmic adaptor protein [92, 97, 167, 168]. Although the 
arrangement of the genes that encode RND components varies among organisms, they 
can be found in a single operon in organisms such as Pseudomonas aeruginosa (e.g. 
mexAB-oprM) and Campylobacter jejuni (e.g. cmeABC) [97, 169].  When genes encoding 
the MexAB-OprM efflux pump in P. aeruginosa and the CmeABC efflux operon in C. 
jejuni are inactivated, a significant decrease in the MICs for various β-lactams, 
chloramphenicol, ciprofloxacin, erythromycin, nalidixic acid, and tetracycline is observed 
[168, 170-172].   
 
The 18 CDS identified by RAST analysis as components of tripartite RND efflux 
pumps were all identical in OSUVM-1 and OSUVM-2 at the nucleotide level. These 
genes presented as six, three-gene operons, organized in the same manner as the mexAB-
oprM and cmeABC operons.  The OSUVM-1 and OSUVM-2 RND inner membrane 




adaptor proteins demonstrated 24 - 27% amino acid identity to MexA and CmeA, while 
the outer membrane porins demonstrated 25 - 29% amino acid identity to OprM and 
CmeC.  These homologies only suggest a relationship between these operons and 
characterized RND efflux systems. It should be noted that when Schindler et al. [173] 
cloned and expressed 21 genes putatively identified as encoding efflux proteins in S. 
aureus, none resulted in increased MICs for any of the substrates tested, calling into 
question the function of these genes in drug efflux.  As a result, it is important that the 
putative efflux genes from Elizabethkingia isolates be confirmed as drug resistance efflux 
pumps through biochemical analysis.   
 
3.1.5 Antimicrobial susceptibility testing 
Both OSUVM-1 and OSUVM-2 demonstrated high MICs for cefazolin, ceftazidime, 
ceftiofur, ampicillin, penicillin, ticarcillin, ticarcillin + clavulanic acid, imipenem, 
amikacin, gentamicin, chloramphenicol, fusidic acid, and tetracycline (Table 4).  While 
the confirmed active β-lactamases in Elizabethkingia are known to contribute to 
resistance to a wide array of antibiotics that target penicillin-binding proteins [45-47], 
other mechanisms such as multidrug efflux, outer membrane alterations and penicillin-
binding proteins that demonstrate reduced affinity for β-lactams can also contribute to β-
lactam resistance, although these mechanisms remain untested in Elizabethkingia [91, 
170, 171].  OSUVM-1 demonstrated an oxacillin MIC of 0.25 mg/l, while OSUVM-2 
showed a higher oxacillin MIC (≥ 4 mg/l), and overall OSUVM-2 displayed higher MICs 





Table 4.  Minimum inhibitory concentrations for select antibiotics determined by the 
Sensititre system or broth microdilution method. Antibiotics displaying different MICs 
are highlighted in bold. 
Antibiotic OSUVM-1 MIC (mg/L) OSUVM-2 MIC (mg/L) 
Amikacin 16 32 
Ampicillin > 32 > 32 
Azithromycin 2 4 
Cefazolin > 16 > 16 
Ceftazidime 64 64 
Ceftiofur 4 4 
Chloramphenicol 8 32 
Ciprofloxacina 0.25 0.25 
Clarithromycin ≤ 1 4 
Clindamycina 1 1 
Doxycycline ≤ 2 ≤ 2 
Enrofloxacin ≤ 0.25 ≤ 0.25 
Erythromycin 1 8 
Fusidic acida 16 16 
Gentamicin 4 > 8 
Imipenem > 8 > 8 
Oxacillin + 2% NaCl ≤ 0.25 > 4 
Penicillin > 8 > 8 
Rifampin ≤ 1 ≤ 1 
Tetracycline 8 > 8 
Ticarcillin 64 > 64 
Ticarcillin + clavulanic acid 64 64 
Trimethoprim + 
sulfamethoxazole 
≤ 0.5 4 
Vancomycina 8 32 





identical in both strains, these MIC differences may be attributed to unidentified SNPs or 
specific gene content differences outside the core genome. 
 
Both OSUVM-1 and OSUVM-2 demonstrated low MICs to ciprofloxacin and 
enrofloxacin, suggesting they are susceptible to these fluoroquinolones (Table S2).  
Ciprofloxacin resistance in Gram-negative bacteria is driven primarily by mutations in 
the gene encoding the DNA gyrase A subunit (gyrA), and resistance is enhanced in both 
cases by mutations in gyrB, parC, and parE [174-179]. The E. anophelis gyrA encodes a 
predicted protein of 858 amino acids, and Perrin et al. [4] identified a Ser83Ile mutation 
in the gyrA of an E. anophelis strain isolated during the 2016 Wisconsin outbreak that 
displayed an increased ciprofloxacin MIC.  Lin et al. [76] subsequently identified the 
same mutation in another E. anophelis strain which also demonstrated an elevated 
ciprofloxacin MIC.  Thus, it is probable that the gyrA mutation Ser83Ile imparts 
ciprofloxacin resistance in E. anophelis, as it does for E. coli [180-185].  Both OSUVM-1 
and OSUVM-2 contain the wild-type serine at position 83, along with two mutations 
when compared to E. anophelis R26, Val841Ala and Ala842Ile.   Positions 841 and 842 
lie outside of the region of gyrA thought to be responsible for fluoroquinolone resistance 
[174, 175, 180, 182] and the low fluoroquinolone MICs demonstrated by both strains are 
consistent with the expectation that these mutations would not convey fluoroquinolone 
resistance.  
 
Vancomycin is used extensively for treating Gram-positive infections, in 




negative organisms are normally intrinsically refractory to the action of vancomycin and 
exhibit MICs > 64 mg/L [122, 124, 188, 189], except Elizabethkingia, which have been 
reported to exhibit vancomycin MICs as low as 1 mg/L [77, 87, 89, 107, 143, 158].  
Vancomycin has been used singly or in combination therapies to treat Elizabethkingia 
infections with mixed success (reviewed in [143]). Furthermore, Hazuka et al. [190] 
reported that when an isolate of E. meningoseptica was exposed to vancomycin for 6 
days, the MIC increased from 8 mg/l to 64 mg/l.  Vancomycin dosing recommendations 
suggest that a serum trough concentration of between 15 to 20 mg/L should be reached 
and maintained to kill susceptible organisms, but this guidance requires that the target 
organism has a vancomycin MIC < 1 mg/L [186, 187, 191]. Using this standard, 
OSUVM-1 and OSUVM-2 (vancomycin MICs = 8 and 32 mg/L, respectively) would be 
resistant to vancomycin.   
 
Here we report the first two draft genomes from Elizabethkingia associated with 
horses, and that these two isolates are closely related to isolates derived from human 
infections, although to date no direct evidence for transmission of Elizabethkingia 
between humans and animals has been observed.  We further demonstrated that both 
isolates display low MICs for ciprofloxacin and that both isolates display vancomycin 
MICs that are within the range of those reported for other E. anophelis isolates [19, 44, 
86, 87, 143, 192].  These comparatively low vancomycin MICs piqued our interest, and 






3.2 Evaluation of the impact of vancomycin on Elizabethkingia  
While vancomycin is utilized as a treatment for Elizabethkingia infection, to date 
there are no studies that have investigated the physiological effects of vancomycin on the 
Elizabethkingia [143].  It is critical to understand these effects in order to better inform 
the use of this antibiotic for treatment of these infections, and to understand how 
vancomycin interacts with Gram-negative organisms.  Therefore, we assayed cell 
survival in the face of vancomycin challenge by kill curve assay, and expanded on the 
previous work of Di Pentima et al. [158] by evaluating vancomycin synergy for our 
collection of 21 genomically-characterized isolates representing six Elizabethkingia 
species. 
 
3.2.1 Vancomycin kills Elizabethkingia in a species-dependent manner 
Exponential phase cultures of E. bruuniana, E. miricola, and E. ursingii 
experienced no decrease in viable cell counts for the first 16 h of exposure at any 
vancomycin concentration (Figure 3).  Two isolates, E. bruuniana ATCC 33958 and E. 
ursingii G4122 showed a decrease in viable cells at 24 h post vancomycin challenge, 
although it is unclear if this decrease is due to the action of vancomycin or other factors 
such as depletion of nutrients. In contrast, E. anophelis, E. meningoseptica, and E. 
occulta cultures all demonstrated decreases in viable cell counts at vancomycin 
concentrations 1.5 X the MIC and at the MBC (Figure 3).  Viable cell counts began to 
decline 2 h after exposure to vancomycin and continued until 6 to 8 h post challenge.  In 
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E. ursingii G4122
Figure 3. Kill curves for the Elizabethkingia type strains exposed to vancomycin in 
mid exponential phase. The growth control is denoted by open circles, while 
increasing concentrations of vancomycin (1 X MIC, 1.5 X MIC, and 1 X MBC) are 

































cultures by 24 h post exposure.  This data suggests that vancomycin resistance in the 
Elizabethkingia could readily emerge at bactericidal concentrations that were 
subsequently used to select for vancomycin-resistant mutants of E. anophelis and E. 
ursingii in section 3.4. 
 
3.2.2 Vancomycin challenge leads to cell death 
While the kill curve data shows that there is a reduction in the number of viable 
cells, and therefore indirectly suggests that vancomycin is causing cell death, it was 
important that we obtain direct evidence that vancomycin exposure was leading to cell 
death.  Therefore, live cell microscopy was used to directly visualize E. anophelis cells 
challenged with vancomycin, and revealed alterations in cell morphology that are 
consistent with disruption of the cell wall, along with debris in the viewing fields that 
were consistent with cell death [131, 132, 137, 193, 194].  Maintenance of the integrity of 
the peptidoglycan cell wall is a tightly regulated competition between peptidoglycan 
biosynthesis and peptidoglycan removal through remodeling and recycling of aging or 
damaged areas of the peptidoglycan layer [194].  Inhibition of peptidoglycan biosynthesis 
leads to weaknesses in the peptidoglycan layer as the peptidoglycan recycling systems 
continue to function normally.  In turn, weaknesses will emerge in the peptidoglycan 
layer and eventually the integrity of the peptidoglycan layer will fail at these weak points, 
at which point the turgor pressure within the cell will push the cytoplasmic membrane 
and contents through the breach [194].  This phenotype was observed in both E. 
anophelis R26 and E. ursingii G4122 cells challenged with vancomycin (Figures 4 and 




Figure 4. Phase contrast images of Elizabethkingia R26 and vancomycin-resistant 
mutant strains after 4 h incubation in MHB with 1.5 X the minimum inhibitory 
concentration of vancomycin.  Arrows point to representative cells displaying the 
dying phenotype.  Round phenotypes were not seen for R26 parent and mutant strains. 





Figure 5. Phase contrast images of Elizabethkingia G4122 and vancomycin resistant 
mutant strains after 4 h incubation in MHB with 1.5 X the minimum inhibitory 
concentration of vancomycin. Arrows point to representative cells with dying 




weakening of the cell wall and death.  These results are similar to those reported by 
Huang et al. [131] when they challenged E. coli mutants demonstrating susceptibility to 
vancomycin with 1 mg/L of vancomycin and noted abnormalities in cell morphology, 
followed by blebbing, and eventually rupture and release of the cytoplasm. 
 
3.2.3 Vancomycin synergism is species-dependent 
To date, only a single study has assessed vancomycin synergism in the 
Elizabethkingia, and unfortunately this work was done before accurate speciation was 
available [158].  In this study Di Pentima et al. tested vancomycin in combination with 
ciprofloxacin, linezolid, and rifampin.  Vancomycin was found to be synergistic with 
rifampin for 3 of the 4 isolates tested, while all 4 isolates displayed additivity for 
vancomycin in combination with ciprofloxacin and linezolid.   
 
Ciprofloxacin in combination with vancomycin displayed additivity for all E. 
anophelis isolates tested, and synergism for all E. meningoseptica, while this combination 
displayed indifference against all E. bruuniana, E. miricola, E. occulta, and E. ursingii.  
A similar pattern was found for rifampin in combination with vancomycin, with E. 
anophelis and E. meningoseptica displaying either synergistic or additive interactions, 
and the other four species being indifferent.  There were two notable exceptions: E. 
bruuniana ATCC 33958T displayed antagonism between rifampin and vancomycin, 
while E. ursingii G4123 displayed additivity between the two compounds (Table 5).   The 
observed synergies of the E. anophelis and E. meningoseptica isolates are consistent with 







Table 5: Fractional inhibitory concentration indices (FICI) and interpretations for all 21 Elizabethkingia isolates. 
 
Isolate Species Ciprofloxacin FICI Interpretationa Rifampin FICI Interpretationa 
R26 anophelis 0.52 Additive 0.25 Synergistic 
F3543 anophelis 0.56 Additive 0.53 Additive 
F3201 anophelis 0.53 Additive 0.25 Synergistic 
3375 anophelis 0.63 Additive 0.31 Synergistic 
422 anophelis 0.52 Additive 0.25 Synergistic 
333 anophelis 0.63 Additive 0.26 Synergistic 
514 anophelis 0.51 Additive 0.52 Additive 
E6809 anophelis 0.56 Additive 0.25 Synergistic 
ATCC 33958 bruuniana 1.00 Indifferent 3.00 Antagonistic 
G0146 bruuniana 1.00 Indifferent 2.00 Indifferent 
G0153 bruuniana 1.50 Indifferent 2.00 Indifferent 
G4075 bruuniana 0.27 Synergistic 2.00 Indifferent 
KC1913 meningoseptica 0.28 Synergistic 0.14 Synergistic 
G4076 meningoseptica 0.25 Synergistic 0.25 Synergistic 
G4120 meningoseptica 0.19 Synergistic 0.14 Synergistic 
G4071 miricola 1.00 Indifferent 1.00 Indifferent 
G4074 miricola 1.50 Indifferent 2.00 Indifferent 
G4121 miricola 1.00 Indifferent 2.00 Indifferent 
G4070 occulta 1.50 Indifferent 1.00 Indifferent 
G4122 ursingii 1.00 Indifferent 1.00 Indifferent 
G4123 ursingii 1.00 Indifferent 0.63 Additive 




bruuniana, E. miricola, E. occulta and E. ursingii, all of which displayed indifference to 
vancomycin in combination with both ciprofloxacin and rifampin.  This suggests that 
there are important species dependent interactions in vitro, and highlight the importance 
of determining the species of the infecting Elizabethkingia isolate before initiating 
combination therapy.  Having demonstrated that vancomycin exposure leads to cell 
death, we wanted to further investigate the impact of vancomycin exposure on a 
transcriptional level within Elizabethkingia. 
 
3.3 Transcriptional profiling of vancomycin challenge 
The transcriptional response of Gram-negative organisms such as Elizabethkingia 
to vancomycin challenge remains poorly understood, but has the potential to reveal 
important information about how vancomycin is disrupting the cell, and leading to cell 
death.  Due to the cell wall active nature of vancomycin, combined with the importance 
of outer membrane permeability in resisting the action of vancomycin, I hypothesized 
that genes involved with cell wall stress and outer membrane permeability would be 
significantly altered in vancomycin challenged cells.  To evaluate this hypothesis E. 
anophelis R26 cells were challenged with 12 mg/L (1.5 X vancomycin MIC) for 30 min 
and gene expression was probed by RNAseq.  E. anophelis R26 was picked for this 
experiment because this isolate is the type strain of E. anophelis, which are the most 






3.3.1 Assembly and mapping 
Assembled Illumina reads mapped to all 3,704 predicted non-rRNA coding sequences, of 
which 114 were significantly upregulated (≥ 2-fold change, FDR ≤ 0.05, Table 6), while 
111 were significantly downregulated (Table 6).  A complete list of all significantly 
altered genes can be found in Appendix B.  These 225 genes represented 11 major 
functional categories, of which the most upregulated functional categories were 
hypothetical genes, genes related to amino acid and protein metabolism, central 
metabolism, and genes related to transport, while amino acid and protein metabolism, 
hypothetical genes, transport genes, central metabolism, and cell envelope metabolism 
represented the most down regulated functional categories (Table 6).   
 
3.3.2 Cell envelope metabolism 
Genes related to the cell envelope were poorly represented among significantly altered 
genes, with only 4 significantly upregulated, while 10 were significantly downregulated.  
Two of these significantly downregulated genes were related to peptidoglycan turnover: a 
putative polysaccharide deactylase that shares a conserved domain with a poorly 
characterized Helicobacter pylori gene that is thought to modify peptidoglycan by 
converting (S)-allantoin into allantoic acid [195], which may function to conceal the 
highly immunogenic moieties of the cell wall from the host immune response [195], and 
a muramidase similar to the flagellum specific hydrolase flgJ [196].  This peptidoglycan 
hydrolase is known to be involved in the remodeling of the peptidoglycan layer in motile 
organisms to allow for the insertion and assembly of the flagellar motor assembly [196].  




Table 6. Functional categories and number of significantly altered genes. 
 
  
Gene functional category Up-regulated Down-regulated 
Amino acid and protein metabolism 21 36 
 Amino acid metabolism 12 8 
 Protein fate 3 2 
 Protein synthesis 6 26 
Antimicrobial resistance 3 3 
Cell envelope metabolism 4 10 
 Cell envelope 1 4 
 Peptidoglycan biosynthesis 2 4 
 Peptidoglycan turnover and remodeling 1 2 
Central metabolism 18 11 
 Carbohydrate metabolism 2 0 
 Cofactors and secondary metabolites 4 4 
 Energy production and conversion 10 1 
 Nucleotide metabolism 1 6 
 Sulfur metabolism 1 0 
DNA replication, recombination, repair 3 1 
Fatty Acid Metabolism 4 2 
Hypothetical/Unknown Function 37 28 
Stress response 8 3 
Transcription and Regulation 3 1 
Transport 10 13 
 Amino acids 0 0 
 Anions 2 1 
 Carbohydrates 3 2 
 Cofactors and secondary metabolites 0 2 
 Metal ions 5 6 
 Osmotic regulation 1 0 
 Protein secretion 0 1 
 Indeterminatea 0 1 
Virulence factors 2 3 
Total 114 111 




considering that these organisms are non-motile, and there is no evidence to date that 
these organisms express any flagella [27, 29].  It is a possibility that this protein is 
serving instead as peptidoglycan hydrolase involved in remodeling the peptidoglycan 
layer in preparation for cell division and it is known that enzymes bearing similar 
conserved domains serve this purpose in Lactococcus lactis [197], and Streptococcus 
faecalis [198].  The remaining 8 genes were evenly distributed between peptidoglycan 
biosynthesis, where two putative glycosyltransferase genes, along with the aspartate 
racemase gene murI and a putative septum formation inhibitor protein were significantly 
downregulated, and genes associated with the cell envelope.  These genes included 3 
porin family proteins, and a low molecular weight phosphotyrosine protein phosphatase. 
 
The 4 upregulated cell envelope metabolism genes consisted of a linear amide C-
N hydrolase with a poorly defined function, a putative motB flagella related protein, outer 
membrane porin (OMP) W, and a gene annotated as an ATP binding protein, but 
identified by conserved domain search as the stress response protease ftsH.  The putative 
motB, ompW, and ftsH genes all are induced in response to cell wall stress stimuli, 
specifically the Cpx and Rcs systems [117, 119, 122, 129, 132, 133, 135-137, 139, 199-
202].  Alterations in ompW expression are widely reported under a variety of 
environmental stressors including osmotic [203], oxidative [200, 204], temperature stress 
[202], and iron limited growth conditions [201].  OmpW is also associated with 
resistance to ampicillin and ceftriaxone, which are cell wall active β-lactam antibiotics, 
along with tetracycline, where it is speculated to partner with multidrug efflux pumps to 




a substrate recognized by known multidrug efflux pumps [122], and as a result it is 
unlikely that OmpW is functioning as a partner in the efflux of vancomycin, although this 
possibility cannot be ruled out.  The ftsH protease is induced in Gram-negative organisms 
by the Cpx misfolded protein periplasmic stress response, while the putative motB is 
induced by the Rcs stress response system [133, 135-137, 139, 199].  The upregulation of 
these genes related to cell wall stress, combined with the downregulation the of 3 porin 
type genes suggests that we are observing the early stages of cell wall stress response in 
these organisms, and provide support for the hypothesis that vancomycin challenge 
induces cell wall stress responses.  
 
3.3.3 Protein synthesis 
Protein synthesis was significantly reduced in the presence of vancomycin 
challenge, and 26 out of 36 total downregulated genes in this category encoded proteins 
putatively associated with translation.  Fifteen of these genes encoded for proteins that 
are structurally associated with the small or large ribosomal subunits, while two (the 
translational GTPase typA, and the ribosome-associated trigger factor) are involved in the 
translation and stabilization of the nascent polypeptide [206].  Six genes were involved in 
the modification of bases in tRNAs, including the highly conserved modifications at 
positions 34 (the wobble position in the codon/anticodon pair) and position 37, which is 
required for accurate pairing and prevention of frameshifting [207].  These genes encode 
for a putative threonylcarbamoyl-AMP synthase, the S-adenosylmethionine (SAM) 
ribosyltransferase-isomerase gene queA, the threonylcarbamoyltransferase ATPase 




functions, and the tRNA guanosine methyltransferase trmB.  The preprotein translocase 
subunit secD was also significantly downregulated, as was the redox-regulated ATPase 
ychF.  In addition, the ribosome-associated inhibitor protein raiA was significantly 
upregulated.  This protein is known to alter the structure of the ribosome to prevent 
translation, and leads to the formation of inactivated 100s ribosome super complexes 
[208]. 
 
These alterations suggest a global downregulation of translation which is a 
common feature of a diverse array of stress responses as the cell shifts resources away 
from energy intensive growth and translation towards survival and stressor specific 
responses, and likely represent a conserved basal stress response that is initiated in the 
early stages of cell stress. 
 
3.3.4 Amino acid and central metabolism 
Genes associated with central metabolism showed the greatest differential 
regulation, with 10 genes significantly upregulated, while only a single gene (ATP 
synthase F1 subunit γ) was significantly downregulated.  Three subunits of the succinate 
dehydrogenase complex were significantly upregulated, along with malate 
dehydrogenase.   The catabolism of phenylalanine was upregulated through the paa 
operon [209], 4 genes of which were upregulated.  This operon degrades phenylalanine to 





These central metabolism alterations suggest that the cells are in the process of 
transitioning from aerobic growth to anaerobic growth.  The upregulation of alcohol 
dehydrogenases along with the upregulation of the cytochrome c accessory protein ccoG, 
which is known to aid in the detoxification of reactive oxygen species [210] supports this, 
as this gene is upregulated during microaerobic and anaerobic growth [211], and it is 
possible that these enzymes may also help to deal with oxidative stress.  The hypothesis 
that the cell is positioning itself to deal with oxidative stress potentially caused by 
disruption of energy production is further supported by the upregulation of genes 
involved in cysteine biosynthesis and phenolic acid breakdown.  Both of these operons 
are known to be induced by oxidative stress [209, 212].  The metabolic and amino acid 
metabolism alterations do not appear to support the hypothesis that vancomycin 
challenge leads to osmotic stress, as genes for the synthesis of neither glycine/betaine nor 
proline were significantly altered, although due to the overlapping nature of many genes 
in the oxidative and osmotic stress response, this hypothesis cannot be discounted [213, 
214].  The downregulation of the F1 subunit of ATP synthase is consistent with cell wall 
stress, as accumulation of unbound subunits in the cytoplasmic membrane is known to be 
toxic to the cell, and serves as an inducer for the Cpx stress response [133]. 
 
3.3.5 Metal ion transport 
Ten genes involved in metal ion transport were significantly altered by 
vancomycin challenge.  Vancomycin is known to function as a chelator of Zn2+ and Cu2+ 
[110], and vancomycin challenge of Streptomyces coulicor was shown to induce genes 




anophelis R26 all 6 significantly downregulated metal ion transport genes were related to 
the uptake of Zn+2 and Cu+2.  Instead, the four significantly increased metal ion 
transporters were predicted to function in the uptake of Fe2+, which is not strongly 
chelated by vancomycin [110]. 
 
3.3.6 Stress response 
Nine total genes related to stress response were significantly altered, 6 up- and 3 
downregulated.  The 3 significantly downregulated genes consisted of a poorly 
characterized transcriptional accessory factor similar to the tex gene in Bordetella 
pertussis and Pseudomonas aeruginosa where it is thought to regulate toxin expression 
[215].  The second downregulated gene was a protein annotated to contain a META 
domain, which is thought to be involved in the heat shock response [216].  The final gene 
was an uncharacterized helix-turn-helix transcriptional regulator with a conserved 
domain similar to the xenobiotic response element family [155].  The stringent response 
is a starvation induced response that occurs when amino acids are limited [217], and is 
characterized by the cessation of translation along with the upregulation of amino acid 
biosynthesis pathways.  This response is mediated by the synthesis of the alarmone 
(p)ppGpp by relA [218], and effects this response in part by binding to the RNA 
polymerase complex to inhibit transcription [218].  No genes related to starvation-
induced stress response through (p)ppGpp production were significantly altered in E. 
anophelis R26 following vancomycin challenge, suggesting these changes are occurring 





Instead, genes involved with the osmotic or oxidative stress responses were 
upregulated, including aquaporin Z, all 3 genes from the tripartite DL-methionine ABC 
transporter, a lipid hydroperodixe peroxidase, and 3 putative membrane stress response 
proteins.  While aquaporin Z and the DL-methionine ABC transporter are upregulated 
during osmotic stress in Gram-negative organisms [219], these genes are also upregulated 
during oxidative stress in E. anophelis NUHP1 and other Gram-negative organisms [75, 
219].  This association, combined with the induction of the lipid hydroperoxide 
peroxidase, the induction of genes related to cysteine biosynthesis, and the lack of genes 
associated with glycine/betaine and proline biosynthesis argues in favor of an oxidative 
stress response.  It should be noted, however, that superoxide dismutase was not 
significantly altered, which in turn argues that these genes are being induced as part of a 
general stress response.  Finally, the acyl-CoA dehydrogenase gene aidB was also 
significantly induced.  This gene is induced in response to DNA damage, and is thought 
to function by associating with double stranded DNA and destroying alkylating agents 
before they have the opportunity to damage the DNA [215]. 
 
3.3.7 The vancomycin stimulon displays features of both the cell wall and oxidative 
stress responses 
It has been suggested that antimicrobial agents kill microorganisms in part by the 
induction of reactive oxygen species generated by disruption of central metabolism, 
although this hypothesis is controversial [125, 220-222].  On the one hand, live cell 
imaging showed evidence of cell wall damage characterized by blebbing and the 




this by revealing the upregulation of genes associated with both the Cpx and Rcs cell wall 
stress response systems [136, 137], along with the alteration of genes associated with cell 
wall synthesis and maintenance, although at 30 min the number of significantly altered 
cell envelope associated genes and it should be noted that no significant alteration was 
found in any genes in the putative capsular synthesis gene cluster (associated with Rcs 
response activation) [135] nor upregulation of the periplasmic stress response chaperone 
CpxP [133, 199], a primary effector of the Cpx pathway.  Other genes unique to the Cpx 
response pathway include periplasmic regulator spy, which did not display significant 
alteration in the E. anophelis R26 RNAseq, and the OM associated complex tolAB, which 
was also not significantly altered [199]. 
 
Surprisingly, RNAseq revealed the alteration of several genes associated with the 
oxidative stress response, including genes associated with iron uptake, osmotic/oxidative 
shock, and a lipid hydroxyperoxidase thought to act on long chain fatty acid alkyl 
hydroperoxides [223], showing that the early stage stress response induced by 
vancomycin challenge shares many hallmarks of the oxidative stress response.  These 
findings suggest there is some evidence that vancomycin challenge leads to oxidative 
damage along with disrupting peptidoglycan biosynthesis, although more investigation 
into this possibility is required.  It should be noted that the vancomycin challenge only 
lasted for 30 min, and it is possible that this is insufficient time to fully induce stress 





3.4 Isolation and characterization of E. anophelis R26 and E. ursingii G4122 isolates 
demonstrating vancomycin resistance.   
As described in project 3.2 above, I evaluated the physiological aspects of 
vancomycin challenge against Elizabethkingia.  This study revealed that cultures 
challenged by vancomycin experienced an initial decrease in viable cell counts followed 
by a rapid rebound to cell densities comparable to the unchallenged control cultures.  
This raised the prospect that mutants demonstrating increased resistance to vancomycin 
arose in normal laboratory media containing growth inhibitory concentrations of 
vancomycin.  In this project I aimed to isolate mutants demonstrating vancomycin 
resistance by selection on media containing vancomycin and to characterize the genomic 
mutations associated with this resistance along with the phenotypic consequences of 
these mutations.  As with the transcriptiomic investigation in project 3.3, E. anophelis 
R26 was chosen for this experiment as it is the type strain for the most important of the 
Elizabethkingia species causing human disease, while E. ursingii G4122 was chosen for 
the selection of mutants due to the low MIC of this isolate (2 mg/L) compared to other 
species (Table 7). 
 
3.4.1 Mutants demonstrating enhanced resistance were isolated after a single 
exposure to vancomycin 
Both E. anophelis and E. ursingii mutants demonstrating elevated resistance to 
vancomycin were selected following exposure to growth inhibitory concentrations of 
vancomycin.  All 8 Elizabethkingia mutants demonstrated elevated vancomycin 




Table 7. Vancomycin MICs and MBCs for parent and vancomycin-resistant mutants. 
  
Isolate Selection concentrationa Mutation frequency MICa MBCa 
R26T - - 8 16 
R26-VR1 16 4.33 x 10-4 128 > 256 
R26-VR2 16 4.33 x 10-4 64 128 
R26-VR3 16 4.33 x 10-4 64 128 
G4122T - - 2 4 
G4122-VR6 12 5.34 x 10-3 64 > 256 
G4122-VR7 14 4.28 x 10-4 32 > 256 
G4122-VR8 16 2.28 x 10-4 32 > 256 
G4122-VR9 18 5.58 x 10-5 > 256 NTb 
G4122-VR10 20 1.23 x 10-5 > 256 NTb 
a mg/L 




for E. anophelis R26-VR1 (VR = vancomycin resistant) and all 5 E. ursingii G4122-VR 
mutants demonstrated MBCs > 256 mg/L, while E. anophelis R26-VSR2 and -VSR3 
demonstrated MBCs of 128 mg/L. These MICs represent an increase over the MIC of the 
E. anophelis R26 and E.ursingii G4122 parent strains (MIC = 8 mg/L and 2 mg/L, 
respectively; Table 7).  The mutation frequency for the 3 E. anophelis mutants was 4.33 x 
10-4, while the mutation frequencies for the 5 E. ursingii mutants ranged from 5.34 x 10-3 
at a vancomycin concentration of 12 mg/L to 1.23 x 10-5 at 20 mg/L (Table 7).  These 
mutation frequencies are considerably higher than those we have observed for mutants 
displaying ciprofloxacin (10-8) and rifampin (10-9) resistance (data not shown). 
 
3.4.2 Temperature and MICs 
Decreasing temperatures are hypothesized to decrease membrane fluidity leading 
to transient gaps in the outer membrane allowing the ingress of agents such as 
vancomycin that are normally excluded from the outer membrane [224].  Therefore, 
examining how vancomycin MICs vary across an array of temperatures for both E. 
anophelis R26 and E. ursingii G4122 and the vancomycin-resistant mutants derived from 
these isolates may provide additional evidence for the mechanisms of vancomycin 
resistance that have been altered in these mutants.  If vancomycin resistance in the 
mutants is largely driven by alterations in outer membrane permeability we would expect 
that as temperature decreases and therefore membrane permeability increases, at low 
temperatures (i.e. 15°C) there should be very little difference in MICs between the parent 
and mutant isolates.  On the other hand, if the mutation(s) underlying vancomycin 




D-ala-D-ala stems [225], for example, then even at low temperatures we would expect to 
see some elevation of vancomycin MICs in mutants demonstrating accumulation of 
unbound D-ala-D-ala stems compared to mutants with mutations affecting membrane 
permeability due to the extra “protective” effect imparted by the excess of D-ala-D-ala 
stems.  While low temperatures may impact vancomycin binding, it will do so in both 
types of mutant. 
 
For most of the strains analyzed, all demonstrated the lowest vancomycin MIC at 
4ºC.  Most strains (R26, R26-VSR1, R26-VRS2, R26-VRS3, G4122, G4122-VR6, and 
G4122-VR7; Table 8) demonstrated the highest MICS at 21°C, 30°C and 35°C.  Only 
strains G4122-VR8 G4122-VR9 and G4122-VR10 demonstrated higher or equal MICs at 
37°C compared to 21°C, 30°C, and 35°C (Table 8).  This data demonstrates that reducing 
temperature does indeed alter vancomycin MIC levels, in an isolate specific manner. 
 
3.4.3 Gradient plate analysis 
It is often demonstrated that the selection for resistance to a single antimicrobial, alters 
the expression of resistance to mechanistically unrelated antimicrobials [226, 227].  Often 
this results from the activation of intrinsic antimicrobial resistance mechanisms that result 
in relatively low levels of resistance expression [227]. Therefore, we applied the gradient 
plate technique, which is used to determine minor alterations in resistance (less than 2- 
fold [228]) to investigate resistance expression to other antimicrobials in our 
vancomycin-resistant mutants. All vancomycin-resistant isolates grew significantly 







Table 8. Vancomycin MICs for parent and mutant Elizabethkingia isolates at different temperatures. 
Isolate Species 15°C 21°C 30°C 35°C 37°C 
R26T anophelis 4 32 64 64 8 
R26-VR1 anophelis 8 64 64 64 128 
R26-VR2 anophelis 8 32 32 32 64 
R26-VR3 anophelis 8 128 128 128 64 
G4122T ursingii 4 8 16 16 2 
G4122-VR6 ursingii 4 32 32 32 64 
G4122-VR7 ursingii 4 32 64 64 32 
G4122-VR8 ursingii 4 16 32 32 32 
G4122-VR9 ursingii 32 64 64 128 > 256 




Table 9. Mean distances grown by E. anophelis R26 and E. ursingii G4122 elevated 
vancomycin resistance mutants on gradient plates for select antibiotics. 
Isolate 
Ciprofloxacin 
0 → 0.5 mg/L 
Clindamycin 
0 → 1 mg/L 
Rifampin 
0 → 0.25 mg/L 
Vancomycin 
0 → 64 mg/L 
R26T 3.67 ± 0.33A 31.00 ± 1.15A 41.33 ± 1.76A 6.33 ± 0.67NT 
R26-VR1 7.67 ± 0.67BC 65.67 ± 1.45B 63.67 ± 2.60B 90.00 ± 0.00 
R26-VR2 7.00 ± 0.58C 52.67 ± 1.20C 70.33 ± 2.03B 89.00 ± 1.00 
R26-VR3 9.67 ± 0.33B 61.67 ± 2.19B 80.33 ± 1.45C 90.00 ± 0.00 
Isolate 0 → 0.25 mg/L 0 → 0.25 mg/L 0 → 0.125 mg/L 0 → 64 mg/L 
G4122T 90.00 ± 0.00NT 7.67 ± 1.53NT 5.33 ± 1.53NT 10.33 ± 0.88NT 
G4122-VR6 7.67 ± 1.03 90.00 ± 0.00 73.67 ± 2.33 24.00 ± 1.53 
G4122-VR7 6.00 ± 0.00 90.00 ± 0.00 89.00 ± 1.00 15.00 ± 1.00 
G4122-VR8 10.33 ± 2.03 90.00 ± 0.00 90.00 ± 0.00 18.00 ± 0.58 
G4122-VR9 7.33 ± 1.00 90.00 ± 0.00 8.00 ± 0.00 90.00 ± 0.00 







vancomycin resistant isolates also demonstrated significantly altered susceptibility to 
ciprofloxacin, clindamycin, and rifampin.  All 3 R26 vancomycin-resistant mutants 
demonstrated significant decreases in susceptibility to all three drugs, while the 5 G4122 
vancomycin-resistant mutants demonstrated increased susceptibility to ciprofloxacin 
compared to the parent strain G4122.  All 5 G4122 vancomycin-resistant mutants 
demonstrated considerable decreases in susceptibility to both clindamycin and rifampin.  
Both of these antibiotics are known to be excluded by the outer membrane of Gram-
negative cells, and this finding suggests that the acquisition of vancomycin resistance 
may also act to enhance the barrier function of the Elizabethkingia outer membrane.  
Alternatively, intrinsic drug efflux pumps are known to affect levels of ciprofloxacin 
resistance in Gram-negative organisms [92, 93, 168, 169, 174, 175, 183, 229-231] and 
these findings may also suggest that enhanced drug efflux might be playing a role with 
ciprofloxacin resistance, although it is less clear in the case of rifampin, which is not an 
efflux pump substrate [232]. 
 
3.4.4 Vancomycin synergism is altered in VR mutants 
Antibiotic combinations are frequently used to empirically treat multiply-
antibiotic resistant Gram-negative organisms in clinical practice [233], with the most 
common combination being a broad-spectrum β-lactam or related antibiotic in 
combination with an aminoglycoside or fluoroquinolone.  These combinations may have 
the benefit of reducing the emergence of antibiotic resistance to either agent alone, 
although evidence for the clinical efficacy of these combinations when treating common 




combination with a second antibiotic, most commonly rifampin or ciprofloxacin, to treat 
Elizabethkingia infections.  The ability of mutations conferring vancomycin resistance to 
alter susceptibility to other antimicrobials, raises the concern that these mutations may 
also impact the synergy between vancomycin and potential antibiotic partners. R26-VR2 
and R26-VR3 demonstrated reduced synergy to vancomycin in combination with 
ciprofloxacin and rifampin, while R26-VR1 displayed no change to ciprofloxacin, and 
improved synergism to rifampin with vancomycin (Table 10).  None of the R26-VR 
mutants demonstrated altered synergies to clindamycin.  All 5 G4122-VR isolates 
demonstrated worse synergism between vancomycin and ciprofloxacin, while 2 isolates 
(VR6 and VR10) demonstrated worse synergy between vancomycin and clindamycin.  
Three isolates (VR7, 8, and 9) demonstrated more favorable synergy for vancomycin in 
combination with clindamycin.  Only G4122-VR10 demonstrated altered synergy 
between vancomycin and rifampin, with this isolate demonstrating improved synergy 
between the two drugs.  These results suggest that alterations to vancomycin 
susceptibility can also lead to alterations in the synergy between vancomycin and other 
antimicrobials through mechanisms that are specific to each isolate.  The observed 
differences in susceptibility amongst mutants further demonstrates the need for rigorous 
antimicrobial testing, and caution when choosing antibiotics or antibiotic combinations to 
treat Elizabethkingia infections. 
 
3.4.5 Effects of vancomycin on cell length 
The inhibition of peptidoglycan biosynthesis, or the inactivation of genes that 







Table 10. Interpretation of vancomycin – antimicrobial synergies. 
Isolate Species 
Ciprofloxacin Clindamycin Rifampin 
FICI Interpretation FICI Interpretation FICI Interpretation 
R26T anophelis 0.500 Synergistic 0.31 Synergistic 0.500 Additive 
R26-VSR1 anophelis 0.260 Synergistic 0.29 Synergistic 0.375 Synergistic 
R26-VSR2 anophelis 1.000 Indifferent 0.50 Synergistic 2.250 Antagonistic 
R26-VSR3 anophelis 1.250 Indifferent 0.38 Synergistic 2.063 Antagonistic 
G4122T ursingii 1.125 Indifferent 0.75 Additive 1.250 Indifferent 
G4122-VR6 ursingii 8.125 Antagonistic 1 Indifferent 1.063 Indifferent 
G4122-VR7 ursingii 18.00 Antagonistic 0.20 Synergistic 1.016 Indifferent 
G4122-VR8 ursingii 40.06 Antagonistic 0.19 Synergistic 1.125 Indifferent 
G4122-VR9 ursingii 8.500 Antagonistic 0.25 Synergistic 1.001 Indifferent 
G4122-VR10 ursingii 4.250 Antagonistic 2.03 Antagonistic 0.501 Additive 




Therefore, we wanted to investigate the morphological consequences of mutations 
underlying vancomycin resistance.  Because at least some of the mutations supporting 
vancomyin-resistance are expected to lead to alterations of either the peptidoglycan layer 
or the outer membrane above, we hypothesized that these mutations would lead to 
alterations in the morphology of the mutant isolates in the presence and absence of  
vancomycin.  We challenged E. anophelis R26 and R26-VR1 with vancomycin for 30 
min, and visualized the resulting cell morphologies by scanning electron microscopy. 
 
No significant difference in cell length was observed between R26 (mean ± 1 
standard error = 1.696 ± 0.04 µm, N = 152) and R26-VR1 (mean ± 1 SE = 1.628 ± 0.03 
µm, N = 157) when grown in MHB alone (Mann-Whitney U-test, N = 309, DF = 308, P 
= 0.32; Table 11). Vancomycin challenged E. anophelis R26 cells were marginally 
shorter (mean ± 1 SE = 1.601 ± 0.04 µm, N = 155) than cells grown in MHB alone 
(Mann-Whitney U-test, N = 307, DF = 306, P = 0.07), while R26-VR1 cells were 
significantly longer (mean ±1 SE = 1.808 ± 0.05 µm, N = 105) than R26-VR1 cells 
grown in MHB alone (Mann-Whitney U-test, N = 262, DF = 261, P = 0.0002; Table 11).  
R26-VR1 cells exposed to vancomycin were significantly longer than E. anophelis R26 
cells exposed to vancomycin (Mann-Whitney U-test, N = 260, DF = 259, P < 0.0001).  
No significant differences were observed in cell width under any condition (Mann-
Whitney U-test, P ≥ 0.149 for all comparisons; Table 11). While no significant 
differences were detected between E. anophelis R26 and R26-V1 isolates grown in MHB 








Table 11.  Mean sizes of E. anophelis R26 and E. anophelis R26-VR1 cells. 
Isolate Treatment Mean cell length ± 1 SEa P-valueb Mean cell width ± 1 SEc P-valueb 
R26 MHB 1.696 ± 0.04 (152) 
0.0712 
635 ± 3.9 (152) 
0.1491 
R26 12 mg/L vancomycin 1.601 ± 0.04 (155) 629 ± 3.7 (155) 
R26-VR1 MHB 1.628 ± 0.03 (157) 
0.0002 
630 ± 6.4 (157) 
0.2729 
R26-VR1 256 mg/L vancomycin 1.808 ± 0.05 (105) 629 ± 9.8 (105) 
a In microns. Parenthesis indicate number of cells measured. 
b Mann-Whitney U-test 




morphology, with E. anophelis R26 demonstrating a marginally significant reduction in 
cell length, while E. anophelis R26-VR1 experienced a significant increase in length. 
   
3.4.6 Identification of mutations leading to vancomycin resistance. 
Antimicrobial resistance often emerges from chromosomal mutations.  These 
mutations can affect the target genes of these antimicrobials, or may occur in genes that 
govern other aspects of antimicrobial susceptibility such as membrane permeability, 
antimicrobial efflux systems, or the production of capsule or biofilm formation [227].  
While the systems governing the vancomycin susceptibility of Gram-negative organisms 
are not yet completely understood, accumulating evidence suggests that vancomycin 
resistance is driven primarily by the permeability of the outer membrane.  It has also been 
demonstrated that vancomycin binds to the terminal D-ala-D-ala stem of the 
peptidoglycan of Gram-negative organisms in a similar manner as the peptidoglycan of 
Gram-positive organisms [131].  This suggests the possibility that mutations in systems 
other than those governing outer membrane permeability such as alterations in the 
thickness or composition of the peptidoglycan, or a reduction in peptidoglycan autolysis 
may have the potential to impact vancomycin susceptibility.  Therefore, we sought to 
identify the mutations underlying the vancomycin-resistant phenotypes using whole 
genome sequencing of all 3 E. anophelis R26-VR mutants along with E. ursingii G4122-
VR6 and G4122-VR10. 
 
Whole genome sequencing of all 3 E. anophelis R26-VR mutants revealed a single 




bioinformatics as a padR transcriptional regulator (Table 12).  These are a large group of 
functionally diverse regulators that demonstrate a winged helix-turn-helix motif [237], 
and are structurally similar to the multiple antibiotic resistance MarR family of 
transcriptional regulators which regulate the expression of the well characterized 
multidrug efflux system AcrAB-TolC [167, 237] as well as other genes [238].  In Gram-
positive organisms, a homologue of the padR regulator in Streptococcus faecalis controls 
expression of an operon with several putative membrane associated proteins, expression 
of which appears to control vancomycin tolerance.  This novel E. anophelis padR 
regulator will from here out be referred to as “vancomycin susceptibility regulator-1” 
(vsr1). The mutation in the R26- VR mutants demonstrated the insertion of a cytosine, 
which resulted in a frameshift and caused amino acid substitutions R75T, Y77I, and 
Y78L, along with a premature stop codon at position 79.  This truncation removes the 
final 34 amino acids of vsr1 and truncated the predicted C-terminal dimerization domain 
[237].  This truncation will likely abolish the ability of Vsr1 to bind to DNA, and abolish 
the regulatory function of this protein. 
 
In contrast, comparison of the G4122-VR6 and G4122-VR10 genomes to the 
G4122 parent genome revealed a total of 5 mutations between the three strains, of which 
2 were unique to G4122-VR6, 1 to G4122-VR10, and the remaining 2 were found in both 
mutants (Table 12). Interestingly, both mutants carried a mutation in a putative  
endonuclease III gene resulting in a phenylalanine to cysteine substitution at position 
136, which is located in the active site and is near both a conserved functionally critical 








Table 12. Location, identity, and sequence outcomes of SNPs. 
Isolate Mutation Location
a Sequence outcome 
All R26-VR Insertion C 1,577,274^1,577,275 
Frameshift truncating the last 34 amino acids of a putative PadR transcription factor, along 
with 3 amino acid substitutions: R75T, Y77I, and Y78L 
All G4122-VR A to C 1,196,035 Synonymous mutation in a putative thioredoxin protein 
All G4122-VR T to G 2,042,612 
F136C amino acid substitution in a putative Endonuclease III gene predicted to be involved 
in base excision repair 
G4122-VR6 Insertion A 452,179^452,180 
Insertion between the predicted -35 box and -10 box for a putative S-layer surface protein-
like M60 Peptidase domain containing hypothetical protein (ORF 723) 
G4122-VR6 G to A 895,352 
Located 36 bp downstream of a putative AraC family helix-turn-helix regulatory protein 
and 7 bp before a putative rteC tetracycline resistance element regulatory protein 
G4122-VR10 G to A 2,454,961 
Nonsense mutation resulting in a premature stop codon at position 256 of a putative β-
lactamase/penicillin binding protein family ORF containing AmpC/penicillin binding 
protein 4A like domain. 




While the functional implications of this substitution have not been elucidated yet, 
a disruption in DNA repair resulting from this mutation in endonuclease III could set the  
stage for additional mutations that resulted in vancomycin resistance.  Both mutants also 
carried a synonymous mutation at nucleotide position 725 in a putative thioredoxin 
reductase gene. It is unlikely that this mutation has any part in the vancomycin resistance 
phenotype displayed by the two mutants.  Both of these mutations were detected 
following comparison with the closed E. ursingii G4122 genome that was completed by 
our collaborators at the CDC.  At the time of writing we have not determined if these two 
mutations are present in our laboratory E. ursingii G4122 stocks, and we speculate that it 
is possible both of these mutations emerged during storage and growth in the laboratory.   
 
G4122-VR6 also contains two mutations in intergenic regions (Table 12). The 
first of these is the insertion of an adenine in the intergenic region between two 
divergently encoded ORFs of 261 and 723 amino acids (Figure 6).  ORF261 encodes a 
putative drug and metabolite transport protein that BLAST analysis revealed contains a 
putative EamA superfamily domain, a diverse and poorly characterized group of 
membrane spanning proteins found in both prokaryotic and eukaryotic organisms thought 
to participate in a wide array of metabolite transport functions, including transport of 
nucleotide and amino sugars [241, 242].  ORF723 encodes a product that is variously 
annotated as a histone acetyltransferase, wall protein precursor, or simply as a 
hypothetical protein in numerous Elizabethkingia genomes.  BLAST analysis of ORF723 












succinogenes major domain.  M60 metalloprotease domains are commonly found in 
extracellular proteins secreted by bacteria that colonize or invade the gut and are thought 
to be responsible for degrading complex glycoprotein matrices such as mucins [243], and 
may also be responsiblefor the formation of amyloid structures on the cell surface [244].  
The Fibrobacter succinogenes major domain is another poorly characterized domain but 
is thought to participate in extracellular complex carbohydrate recognition and binding 
[245]. The bioinformatic information provided about these genes therefore does not help 
is trying to connect them to the vancomycin resistance mechanism. 
 
The 236 bp intergenic region between ORF261 and ORF723 was analyzed using 
the BPROM promoter prediction software [160] to investigate the potential for this 
insertion to alter regulatory elements for one or both nearby ORFs. BPROM identified 13 
potential binding sites for regulatory proteins on the plus strand, and 13 potential binding 
sites on the minus strand (Figures 7 and 8).  Of the 26 predicted regulatory sequences, 4 
predicted sequences on the minus strand, along with the predicted -35 box for ORF 261 
contain the insertion, while two additional sequences are proximal to the insertion (Figure 
7, Table 13).  The second intergenic mutation in G4122-VR6 is an A>G transition in a 43 
bp intergenic region between a putative AraC family transcriptional regulator, and rteC, a 
putative tetracycline response regulator. BPROM did not identify any putative regulatory 
elements in this region [246]. 
 
The unique SNP in G4122-VR10 leads to a nonsense mutation in a gene encoding 








Figure 7. Plus-strand genomic context of the insertion in E. ursingii G4122-VRS6.  Regulatory elements predicted by BPROM are 








Figure 8. Minus-strand genomic context of the insertion in E. ursingii G4122-VRS6.  Regulatory elements predicted by BPROM 




Table 13. Potential regulatory sequences directly impacted by the insertion of a thymine 






-35 box (T)TTTTT 
Binding site for σ70 mediated RNA 
polymerase binding 
Lrp A(T)TTTTTTT 
Regulator of amino acid metabolism and 
pili synthesis [247] 
RpoH2 
(T)TTTTTTT Heat and oxidative stress response [248] 
LexA 
TTTTTTTA 
Stress response regulator, particularly DNA 
breakage SOS response [249] 
ArgR 
TTTTTTAT 
Regulation of arginine metabolism, and 
may activate expression of pili and adhesins 
[250, 251] 






120 amino acids in the vanomycin-resistant mutant (Table 12).  Differentiating between 
β-lactamases and PBPs is complicated by the considerable sequence and domain 
conservation between the two enzyme classes [252]. The PBPs are critical enzymes for  
cell wall biosynthesis, remodeling, and maintenance, and PBP 4A is thought to function 
in the maintenance of cell shape and is known to possess DD-carboxypeptidase activity 
[253], which removes the terminal D-ala residue from the pentapeptide stem on 
peptidoglycan polymers. Both terminal D-ala residues are required for vancomycin to 
bind peptidoglycan [222] and therefore it is possible that the truncation of ORF376 in 
G4122-VR10 may lead to the accumulation of unbound D-ala-D-ala stems binding 
vancomycin away from the site of active cell wall biosynthesis in a similar mechanism to 
that proposed for vancomycin-intermediate S. aureus [126, 127]. 
 
3.4.7 qPCR analysis of vancomycin resistant mutants 
Whole genome analysis of the three E. anophelis R26-VR mutants, along with E. 
ursingii G4122-VR6, revealed the presence of mutations that had the potential to impact 
the expression of genes around them.  Therefore, the expression of three genes, ORF552 
in E. anophelis R26 and R26-VR3 along with ORF261 and ORF723 in E. ursingii G4122 
and G4122-VR6 in the presence and absence of vancomycin was quantified by qPCR. 
 
ORF552 was significantly upregulated in the absence of vancomycin in E. 
anophelis R26-VR3 compared to R26 (mean fold-change ± 1 SE = 11.77 ± 2.25, P = 
0.02; Student’s t-test, N = 3, DF = 2 for all comparisons) (Table 14).  This upregulation 







Table 14. Quantitative PCR analysis of ORF552 in E. anophelis R26-VR3 and ORF261 and ORF723 in E. uringii G4122-VR6. 
Isolate Gene Treatment Mean Fold Change ± 1SE P-valuea 
R26 ORF552 
Control - - 
Vancomycin 1.61 ± 1.28 0.193 
R26-VR1 ORF552 
Control 11.77 ± 2.25b 0.02 
Vancomycin 87.22 ± 1.27c 0.002 
G4122 ORF261 
Control - - 
Vancomycin 1.09 ±0.09b 1.000 
G4122-VR6 ORF261 
Control 5.86 ±0.66b 0.041 
Vancomycin -1.33 ±0.73c 0.436 
G4122T ORF723 
Control - - 
Vancomycin -15.99 ±0.67b 0.047 
G4122-VR6 ORF723 
Control 0.96 ±0.33b 0.976 
Vancomycin 24.27 ±0.67c 0.006 
a Student’s t-test 
b Compared to expression levels in the parent isolate MHB only control 




= 0.002).  ORF552 expression was not significantly altered in the presence of 
vancomycin for neither E. anophelis R26 (1.61 ± 1.28; P = 0.193) nor E. anophelis R26-
VR3 (1.16 ± 1.27; P = 0.680).  This suggests that the truncation of vsr1 in E. anophelis 
R26-VR3 has led to de-repression of ORF552 in this isolate, resulting in significantly 
increased basal expression levels.  The lack of significant change in ORF552 in E. 
anophelis R26-VR3 is consistent with this hypothesis, as the major source of repression, 
vsr1, remains unable to regulate this gene due to the truncation.  More interesting is the 
lack of significant change in E. anophelis R26.  The potential importance of ORF552 in 
vancomycin resistance is suggested by the putative phage shock protein A/C domain that 
was detected in this protein [254].  This domain is one of the major sensor and effector 
proteins for the phage shock protein response [254], and the greater expression of this 
gene in E. anophelis R26-VR3 may increase the ability of this organism to detect 
vancomycin damage early, and activate survival responses that are thus more effective. 
 
Quantitative PCR analysis demonstrated that in the absence of vancomycin 
ORF261 was significantly upregulated in G4122-VR6 compared to G4122 (5.86 ±0.68; P 
= 0.041), but was not significantly altered between the two isolates in the presence of 
vancomycin (-1.33 ± 0.73; P = 0.463).  ORF261 was not significantly altered by 
vancomycin challenge in G4122 (1.09 ± 0.09; P = 1.000) but was significantly 
downregulated in G4122-VR6 (-4.09 ± 0.73; P = 0.016).  Conversely, ORF723 was not 
significantly altered in G4122-VR6 compared to G4122 in the absence of vancomycin 
(0.96 ± 0.33; P = 0.976,) but was significantly upregulated during vancomycin challenge 




downregulation of ORF723 in G4122 (-15.99 ± 0.47; P = 0.047) but not G4122-VR6 
(1.58 ± 0.67; P = 0.082).  These results suggest two possibilities: that the downregulation 
of ORF261 in E. ursingii G4122-VR6 may reduce the permeability of the outer 
membrane by reducing the number of pore proteins inserted into the membrane.  There is 
no evidence to date that vancomycin is capable of passing through the pores of transport 
proteins, but this has not been tested in the case of EamA-like proteins [122].  Secondly, 
it is possible that the adenine insertion in E. ursingii G4122-VR6 has disrupted the 
regulation of ORF723, preventing the downregulation of this ORF during vancomycin 
challenge.  While the specific function of ORF723 is unclear, extracellular 
metalloproteases such as ftsH are upregulated during cell envelope stress, and it is 
possible that ORF723 is functioning in a similar manner. 
  
3.5 Conclusions 
We have demonstrated that Elizabethkingia isolates with significant genomic 
similarity to human isolates are found in horses, although to date no direct evidence for 
transmission of Elizabethkingia between humans and animals has been observed [74].  
We further demonstrated that both isolates display low MICs for ciprofloxacin and that 
both isolates display MICs for vancomycin consistent with those reported for E. 
anophelis isolates from human infections [19, 44, 86, 87, 105, 107, 143, 158, 188, 192, 
255].  This work continues to build evidence that E. anophelis are widely distributed, and 
that additional environmental and epidemiological studies should be carried out to further 





We have also demonstrated that vancomycin displays a bactericidal effect on 
Elizabethkingia, and that these organisms demonstrate vancomycin MICs and MBCs that 
are considerably lower than those normally observed for Gram-negative organisms [188].  
Our results further demonstrate that there are considerable differences between 
Elizabethkingia species to vancomycin in combination with ciprofloxacin and rifampin, 
and that efforts should therefore be made to speciate suspected Elizabethkingia isolates 
prior to the initiation of combination therapy.  It is possible that there are compositional 
differences in the outer membrane of Elizabethkingia isolates, which in turn may lead to 
differences in permeability, and needs to be investigated further. 
 
Vancomycin challenge appeared to induce genes from both the Cpx and Rcs 
stress response systems in E. anophelis R26 following 30 min of exposure. Vancomycin 
challenge further resulted in the upregulation of genes that have been implicated in the 
oxidative stress response, including upregulation of iron uptake genes, alterations to 
components of the TCA cycle, and suppression of translation [75].  It is possible that the 
similarities between these two stress response stimulons points to a conserved cross 
protective underlying stress response, with more specific stress response genes activated 
on top of this basal response.  It should be noted again that a major caveat of this work is 
that vancomycin challenge only lasted for 30 min.  While 30 min challenge is sufficient 
to generate cell wall stress responses in Gram-negative organisms challenged with other 
cell wall active microbials [131, 199], the slower action of vancomycin as evidenced by 
the 2 h lag time between challenge and cell death raises the possibility that a longer 




while it is unlikely that OmpW is functioning in concert with multidrug efflux systems to 
remove vancomycin [122], this possibility cannot be ruled out and should be investigated 
further. 
 
Vancomycin resistance in the Elizabethkingia requires very few mutations to 
occur, and can have dramatic impacts on antimicrobial susceptibility to other antibiotics 
and combinations.  Similar to Gram-positive organisms where vancomycin intermediate 
resistance is known to arise from a diverse array of mutations [109, 126-128, 256, 257], 
our results suggest that there are several different mechanisms for the development of 
vancomycin resistance in the Elizabethkingia.  All 3 sequenced E. anophelis R26 
vancomycin-resistant mutants displayed an identical mutation, however this mutation was 
different than the mutations identified in the two E. ursingii G4122 vancomycin-resistant 
mutants that were sequenced.  A major caveat to this work is that the sequencing data 
was compared to reference genomes, rather than comparison by de novo assembly.  It is 
possible that this method has resulted in other alterations in the genome, such as 
duplications or more significant insertions or deletions, being missed. 
 
All told, we have demonstrated that vancomycin kills Elizabethkingia by 
inhibiting peptidoglycan biosynthesis, although the high mutation frequency of 
vancomycin-resistant mutants, along with the ability of vancomycin resistance to arise 
from mutations in multiple different systems raises concerns about the efficacy of this 




3.6 Future Directions 
In vitro synergy assays are limited because they provide an ideal environment for 
the organism being challenged to grow in while eliminating potentially important host 
factors [258].  The behavior of microorganisms in vitro does not always translate in vivo, 
and it is possible that the impact of vancomycin on Elizabethkingia is a prime example.  
Therefore, to better understand both the role of vancomycin in Elizabethkingia treatment, 
and to better evaluate the impact of mutations conferring vancomycin resistance in a 
clinically relevant setting, it is of critical importance to develop and validate an animal 
model of Elizabethkingia infection.  A functional animal model will allow the 
characterization of host factors (innate immune responses, for example), and will provide 
a better understanding of how these mutations impact fitness and antibiotic susceptibility.   
 
While our microscopy data provides more direct evidence of cell death due to 
vancomycin, imaging does not provide direct evidence of the inhibition of peptidoglycan 
biosynthesis.  Therefore, the inhibitory action of vancomycin should be investigated by 
isolating the peptidoglycan sacculus from cells grown in the presence of 14C-labeled 
peptidoglycan precursors, and quantifying the incorporation of these precursors into the 
cell wall with and without the presence of vancomycin by liquid scintillation 
radiography.  Furthermore, fluorescently labeled vancomycin should be utilized to 
directly visualize vancomycin to assess differences in accumulation between the various 





De novo assembly of the existing whole genome sequencing, along with 
sequencing of the remaining 3 E. ursingii G4122-VR isolates may identify other potential 
mutations, or confirm the known mutations.  RNAseq of the vancomycin-resistant 
mutants is critical to understanding the alterations in these organisms that allow them to 
resist the action of vancomycin, and will allow for the investigation of genes that are 
more specifically involved in the vancomycin response.  Additionally, many of the cell 
envelope stress responses in Gram-negative organisms rely on proteolytic activation of 
response regulators and may not be captured by qPCR or RNAseq assays.  Therefore, 
proteomic analysis of cell wall stress sensors will provide a more detailed analysis of the 
vancomycin stress response in Elizabethkingia, and may help to identify potential targets 
for enhancing the effectiveness of vancomycin in these and other Gram-negative 
organisms. 
 
Finally, the isolation and characterization of a wider collection of E. anophelis 
vancomycin- resistant mutants will help to better understand the prevalence of each of 
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Appendix B: Significantly altered genes in Elizabethkingia anophelis R26 with and without vancomycin. 
GeneID Function Functional Group logFC logCPM FDR 
BAZ09_000165 
AraC family transcriptional 
regulator 
Amino acid and protein 
metabolism 
0.869 6.610 0.005 
BAZ09_000170 
cytochrome c oxidase 
accessory protein CcoG 
Central Metabolism 1.353 6.172 0.008 
BAZ09_000310 hypothetical protein Hypothetical 0.733 5.433 0.010 
BAZ09_000560 hypothetical protein Hypothetical 0.974 7.933 0.004 
BAZ09_000565 hypothetical protein Hypothetical -0.774047 5.25075 0.0111 
BAZ09_000630 hypothetical protein Hypothetical 1.330 10.354 0.008 
BAZ09_000790 HAD family hydrolase Central Metabolism 1.357 6.199 0.004 
BAZ09_000950 ketoacyl-ACP synthase III Fatty Acid Metabolism -0.947927 7.24609 0.0036 
BAZ09_001110 
SusC/RagA family TonB-
linked outer membrane protein 




Central Metabolism -0.755537 5.99570 0.0211 
BAZ09_001410 S1/P1 Nuclease Central Metabolism -0.771453 7.31162 0.0056 




Amino acid and protein 
metabolism 




Fatty Acid Metabolism -0.73563 6.77839 0.0463 




Amino acid and protein 
metabolism 
-1.047153 6.60463 0.0091 














-0.70611 5.38371 0.0165 
BAZ09_001765 polysaccharide deacetylase 
Cell envelope 
metabolism 
-0.838623 5.05939 0.0053 
BAZ09_001770 




-0.820203 5.41120 0.0079 
BAZ09_001910 
molybdenum cofactor 
biosynthesis protein MoaE 
Central Metabolism 0.698 5.259 0.026 
BAZ09_002025 translational GTPase TypA 
Amino acid and protein 
metabolism 
-0.980508 9.37567 0.0046 
BAZ09_002065 
preprotein translocase subunit 
SecD 
Amino acid and protein 
metabolism 
-0.794689 10.6177 0.0052 
BAZ09_002105 hemolysin Virulence -0.859617 4.41428 0.0096 
BAZ09_002110 hypothetical protein Hypothetical -0.884213 8.95163 0.0039 
BAZ09_002120 cytidine deaminase Central Metabolism -1.097429 5.32199 0.0064 
BAZ09_002135 hypothetical protein Hypothetical 0.739 6.205 0.043 
BAZ09_002140 transcriptional regulator Virulence -0.764769 5.46500 0.0136 
BAZ09_002190 
AraC family transcriptional 
regulator 
Transcription -0.70241 4.51333 0.0175 
BAZ09_002235 









Amino acid and protein 
metabolism 
-0.927054 6.04234 0.0131 
BAZ09_002410 
ABC transporter ATP-binding 
protein 
Transport -0.75842 5.00086 0.0091 







BAZ09_002455 septum formation inhibitor 
Cell envelope 
metabolism 
-0.717961 5.51623 0.0337 
BAZ09_002465 
class I SAM-dependent 
methyltransferase 
Amino acid and protein 
metabolism 
-0.755596 5.60580 0.0136 
BAZ09_002495 hypothetical protein Hypothetical -0.745491 6.64568 0.0173 
BAZ09_002545 homoserine kinase 
Amino acid and protein 
metabolism 
1.210 5.851 0.006 
BAZ09_002550 threonine synthase 
Amino acid and protein 
metabolism 
1.660 7.081 0.003 
BAZ09_002620 hypothetical protein Hypothetical -0.926172 5.16849 0.0067 
BAZ09_002625 thioredoxin 
Amino acid and protein 
metabolism 
-1.137691 5.27651 0.0083 
BAZ09_002660 redox-regulated ATPase YchF 
Amino acid and protein 
metabolism 




Hypothetical -0.900568 5.76294 0.019 
BAZ09_002845 SMI1/KNR4 family protein Stress response 0.869 7.034 0.008 
BAZ09_002895 transcriptional regulator Stress response -0.920982 5.12431 0.0204 
BAZ09_002915 hypothetical protein Hypothetical -0.826425 5.49689 0.0089 
BAZ09_002940 
cytochrome D ubiquinol 
oxidase subunit II 
Central Metabolism 0.923 5.727 0.005 
BAZ09_003035 ATP-binding protein 
Cell envelope 
metabolism 




Stress response -0.969999 5.67570 0.0046 
BAZ09_003285 
polyprenyl synthetase family 
protein 




Amino acid and protein 
metabolism 












Amino acid and protein 
metabolism 
-0.731376 9.29714 0.0056 
BAZ09_003345 PorT family protein 
Cell envelope 
metabolism 
-0.785203 11.2012 0.0275 
BAZ09_003350 PorT family protein Transport -0.90356 12.1818 0.0155 
BAZ09_003355 PorT family protein Transport -1.016941 7.52365 0.0176 
BAZ09_003495 hypothetical protein Hypothetical -1.009329 5.57341 0.0336 
BAZ09_003595 30S ribosomal protein S6 
Amino acid and protein 
metabolism 
-0.833909 10.4065 0.008 
BAZ09_003600 30S ribosomal protein S18 
Amino acid and protein 
metabolism 
-0.970738 10.0473 0.0036 
BAZ09_003615 histone H1 Hypothetical -1.325895 10.0289 0.0096 
BAZ09_003695 hypothetical protein Hypothetical -0.7761 9.38959 0.0323 
BAZ09_003780 aminopeptidase 
Amino acid and protein 
metabolism 
-0.799386 7.79109 0.0081 




Stress response -0.774388 6.23684 0.0101 
BAZ09_003980 50S ribosomal protein L19 
Amino acid and protein 
metabolism 
-0.926988 10.8218 0.0036 
BAZ09_004015 EamA family transporter Transport -0.706752 6.6664 0.008 
BAZ09_004025 30S ribosomal protein S1 
Amino acid and protein 
metabolism 




-1.155155 7.60310 0.0044 
BAZ09_004395 
signal recognition particle 
sRNA small type 
Transcription 1.235 4.198 0.025 







BAZ09_004535 lipid hydroperoxide peroxidase Stress response 0.979 11.293 0.021 
BAZ09_004645 
SusC/RagA family TonB-
linked outer membrane protein 
Transport 1.216 5.574 0.004 
BAZ09_004650 
RagB/SusD family nutrient 
uptake outer membrane protein 
Transport 1.184 4.281 0.008 
BAZ09_004710 TonB-dependent receptor Transport 1.350 4.398 0.003 
BAZ09_004715 MFS transporter 
Antimicrobial 
Resistance 
0.971 5.635 0.004 
BAZ09_004720 peptidase M12 Virulence 1.384 4.820 0.004 
BAZ09_004725 hypothetical protein Hypothetical 0.886 4.147 0.017 
BAZ09_005285 short chain dehydrogenase Fatty Acid Metabolism 0.820 4.645 0.031 
BAZ09_005325 vitellogenin ii Hypothetical 0.718 7.102 0.039 




Hypothetical 1.010 4.155 0.025 
BAZ09_005710 N-acetyltransferase Indeterminate 1.009 5.270 0.010 




Central Metabolism -0.739214 7.32775 0.0258 
BAZ09_005810 
thiamine biosynthesis protein 
ThiS 




complex ATPase subunit type 
1 TsaE 
Amino acid and protein 
metabolism 
-0.780429 4.92320 0.0089 
BAZ09_005885 alanine dehydrogenase 
Amino acid and protein 
metabolism 
-0.762286 7.18474 0.0167 







BAZ09_005965 30S ribosomal protein S15 
Amino acid and protein 
metabolism 
-0.782633 10.4279 0.0376 
BAZ09_006215 aspartate kinase 
Amino acid and protein 
metabolism 
-0.759832 5.69816 0.0167 
BAZ09_006320 hypothetical protein Hypothetical 0.898 6.072 0.006 
BAZ09_006325 hypothetical protein Hypothetical 0.997 3.242 0.020 
BAZ09_006335 hypothetical protein Hypothetical 0.945 4.958 0.005 
BAZ09_006755 tRNA-Met 
Amino acid and protein 
metabolism 
0.830 6.529 0.047 
BAZ09_006840 hypothetical protein Hypothetical 1.091 4.731 0.008 
BAZ09_006900 hypothetical protein Hypothetical 0.711 4.027 0.032 
BAZ09_007005 
MerR family transcriptional 
regulator 




Hypothetical 1.581 6.008 0.003 
BAZ09_007035 alcohol dehydrogenase AdhP 
Amino acid and protein 
metabolism 
1.627 7.083 0.006 
BAZ09_007040 aldehyde dehydrogenase Central Metabolism 1.817 8.599 0.004 
BAZ09_007585 
NADPH-dependent 
assimilatory sulfite reductase 
hemoprotein subunit 




Central Metabolism 1.331 4.513 0.005 
BAZ09_007600 cysteine synthase A 
Amino acid and protein 
metabolism 
1.147 4.510 0.006 
BAZ09_007605 serine acetyltransferase 
Amino acid and protein 
metabolism 
1.315 4.059 0.010 
BAZ09_007610 sulfate adenylyltransferase 
Amino acid and protein 
metabolism 










Amino acid and protein 
metabolism 








Stress response 0.913 10.144 0.005 
BAZ09_007705 arginine decarboxylase 
Amino acid and protein 
metabolism 
-1.011218 8.57549 0.0079 
BAZ09_007980 hypothetical protein Hypothetical 1.039 5.519 0.004 
BAZ09_008030 
efflux RND transporter 
periplasmic adaptor subunit 
Antimicrobial 
Resistance 
-0.736008 5.37367 0.0079 
BAZ09_008400 hypothetical protein Hypothetical 0.897 5.321 0.039 
BAZ09_008520 
phenylacetic acid degradation 
bifunctional protein PaaZ 
Amino acid and protein 
metabolism 
0.694 6.877 0.008 




Amino acid and protein 
metabolism 
0.772 4.883 0.032 
BAZ09_008570 
1,2-phenylacetyl-CoA 
epoxidase subunit B 
Amino acid and protein 
metabolism 




Amino acid and protein 
metabolism 
1.105 5.635 0.007 
BAZ09_008640 zinc metalloprotease 
Amino acid and protein 
metabolism 
1.269 6.334 0.003 
BAZ09_008815 hypothetical protein Hypothetical 0.699 4.538 0.017 




Hypothetical -0.756382 9.90817 0.0091 
BAZ09_009090 hypothetical protein Hypothetical -0.999246 5.14505 0.0052 
BAZ09_009360 3-oxoacyl-ACP reductase Fatty Acid Metabolism 0.768 5.363 0.010 







BAZ09_009755 30S ribosomal protein S7 
Amino acid and protein 
metabolism 
-0.783786 9.89100 0.0304 
BAZ09_009920 
RagB/SusD family nutrient 
uptake outer membrane protein 
Transport 1.696 6.697 0.001 
BAZ09_009925 TonB-dependent receptor Transport 1.356 7.493 0.004 
BAZ09_010135 TonB-dependent receptor Transport -0.717373 6.37521 0.0103 




Amino acid and protein 
metabolism 




Amino acid and protein 
metabolism 




Amino acid and protein 
metabolism 
-0.797647 6.80589 0.008 
BAZ09_010435 argininosuccinate synthase 
Amino acid and protein 
metabolism 
-0.763415 8.02057 0.0178 
BAZ09_010440 N-acetyltransferase Hypothetical -0.922193 5.28012 0.0079 
BAZ09_010540 
DoxX family membrane 
protein 
Hypothetical 0.726 6.220 0.047 
BAZ09_010575 hypothetical protein Hypothetical -0.719009 8.09780 0.0071 
BAZ09_010655 




1.093 6.970 0.009 
BAZ09_010700 HlyD family secretion protein 
Antimicrobial 
Resistance 
-0.760215 6.60335 0.0089 
BAZ09_010705 TolC family protein 
Cell envelope 
metabolism 








Central Metabolism -0.842993 8.29742 0.0248 







BAZ09_011540 GLPGLI family protein Hypothetical -0.98176 6.25304 0.0036 
BAZ09_011710 50S ribosomal protein L21 
Amino acid and protein 
metabolism 
-0.878887 10.9004 0.0089 
BAZ09_011715 50S ribosomal protein L27 
Amino acid and protein 
metabolism 
-0.793757 10.1351 0.0083 
BAZ09_012080 hypothetical protein Hypothetical -0.792865 3.75641 0.0177 
BAZ09_012085 hypothetical protein Hypothetical -0.819053 4.68752 0.0214 




Amino acid and protein 
metabolism 
-0.954831 6.80264 0.0167 
BAZ09_012760 50S ribosomal protein L13 
Amino acid and protein 
metabolism 
-0.965751 10.7949 0.012 
BAZ09_012765 30S ribosomal protein S9 
Amino acid and protein 
metabolism 
-0.942313 9.72274 0.013 
BAZ09_012770 30S ribosomal protein S2 
Amino acid and protein 
metabolism 
-1.162682 10.9153 0.0136 
BAZ09_012860 
acetyl-CoA carboxylase, biotin 
carboxyl carrier protein 
Transport -0.855035 8.61621 0.0304 
BAZ09_013215 cysteine--tRNA ligase 
Amino acid and protein 
metabolism 
0.808 9.828 0.040 
BAZ09_013290 30S ribosomal protein S21 
Amino acid and protein 
metabolism 




1.014 8.748 0.020 
BAZ09_013300 
ribosomal subunit interface 
protein 
Amino acid and protein 
metabolism 
1.657 11.398 0.003 
BAZ09_013305 tRNA-Thr 
Amino acid and protein 
metabolism 
1.350 8.406 0.003 
BAZ09_013345 OmpW family protein 
Cell envelope 
metabolism 







BAZ09_013360 50S ribosomal protein L11 
Amino acid and protein 
metabolism 
-0.932828 10.3830 0.0058 
BAZ09_013365 50S ribosomal protein L1 
Amino acid and protein 
metabolism 
-1.378914 10.5952 0.0138 
BAZ09_013370 50S ribosomal protein L10 
Amino acid and protein 
metabolism 
-1.31409 10.6277 0.0045 
BAZ09_013580 
GlsB/YeaQ/YmgE family 
stress response membrane 
protein 
Stress response 0.870 9.284 0.008 
BAZ09_013625 trigger factor 
Amino acid and protein 
metabolism 




Hypothetical -0.787834 5.78976 0.0091 
BAZ09_013780 




0.865 13.362 0.022 
BAZ09_014045 bacteriocin Hypothetical 0.908 6.170 0.028 
BAZ09_014055 hypothetical protein Hypothetical 0.887 4.801 0.006 
BAZ09_014170 recombinase RecA 
DNA Replication, 
Recombination, Repair 








Transport -0.810706 5.23232 0.0335 




Hypothetical 0.741 7.468 0.010 
BAZ09_014405 aquaporin Z Transport 1.392 8.778 0.001 
BAZ09_014540 aspartate racemase murI 
Cell envelope 
metabolism 










Transport -0.69693 7.37241 0.0432 
BAZ09_014690 malate dehydrogenase Central Metabolism 0.839 9.591 0.014 
BAZ09_014920 
ATP synthase F1 subunit 
gamma 
Central Metabolism -0.695977 9.98959 0.0079 
BAZ09_015030 oxidoreductase Central Metabolism 1.308 6.163 0.001 
BAZ09_015185 hypothetical protein Hypothetical 1.192 6.100 0.008 
BAZ09_015195 anion permease Transport 2.714 8.052 0.003 








reductase iron-sulfur subunit 
Central Metabolism 2.323 7.314 0.006 
BAZ09_015335 hypothetical protein Hypothetical 0.930 5.377 0.005 




Hypothetical 0.895 6.917 0.010 
BAZ09_015440 VOC family protein Transport 0.730 4.376 0.040 




Hypothetical -0.937269 6.57341 0.0067 
BAZ09_015760 
ABC transporter ATP-binding 
protein 
Stress response 0.950 7.174 0.003 
BAZ09_015770 hypothetical protein Hypothetical 1.047 4.053 0.006 
BAZ09_015775 hypothetical protein Hypothetical 1.527 4.094 0.003 
BAZ09_015785 vitamin K epoxide reductase 
Amino acid and protein 
metabolism 








Amino acid and protein 
metabolism 
1.196 8.332 0.004 
BAZ09_015795 hypothetical protein Hypothetical 0.860 6.859 0.034 
BAZ09_015850 hypothetical protein Hypothetical 0.705 4.020 0.038 
BAZ09_015855 hypothetical protein Hypothetical 0.925 6.157 0.011 
BAZ09_016030 hypothetical protein Hypothetical -0.818784 6.76456 0.0202 
BAZ09_016185 cytochrome C oxidase Cbb3 Central Metabolism 1.312 12.258 0.009 
BAZ09_016610 hemolysin Virulence 0.802 11.106 0.020 
BAZ09_016625 hypothetical protein Hypothetical 1.155 9.042 0.004 
BAZ09_016690 DNA-binding protein Hypothetical -0.70618 6.01411 0.008 
BAZ09_016930 glycosyl hydrolase Central Metabolism 0.694 6.209 0.008 
BAZ09_017025 hypothetical protein Hypothetical 1.224 6.278 0.017 
BAZ09_017070 




-0.726503 4.07636 0.0318 
BAZ09_017115 VIT family protein Transport 0.989 6.904 0.005 




Amino acid and protein 
metabolism 




Central Metabolism 0.987 7.163 0.020 
BAZ09_017675 





-0.955912 8.77113 0.0082 
BAZ09_017735 hypothetical protein Hypothetical -0.788288 9.51064 0.0082 
BAZ09_017760 insulinase family protein Central Metabolism -0.970784 5.29352 0.0036 
BAZ09_017785 MFS transporter Transport -0.72094 5.42479 0.0197 
BAZ09_017800 hypothetical protein Hypothetical 1.860 10.095 0.001 












Amino acid and protein 
metabolism 
0.775 6.799 0.047 
BAZ09_018020 hypothetical protein Hypothetical 0.780 10.108 0.005 
BAZ09_018025 hypothetical protein Hypothetical -0.840981 9.02751 0.0307 
BAZ09_018030 porin family protein 
Cell envelope 
metabolism 
-1.37215 7.69120 0.0053 
BAZ09_018325 
methionine ABC transporter 
substrate-binding protein 
MetQ 
Transport 1.690 5.589 0.001 
BAZ09_018330 
D-methionine ABC transporter 
permease MetI 












Hypothetical -1.287161 7.08201 0.003 
BAZ09_018655 linear amide C-N hydrolase 
Cell envelope 
metabolism 
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